Till sidinnehåll
Kunskapsbank för cancervården Till cancercentrum.se


Aarnio, M., Mecklin, J. P., Aaltonen, L. A., Nystrom-Lahti, M., & Jarvinen, H. J. (1995). Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer, 64(6), 430-433. 

Abdel-Azeez, H. A., Labib, H. A., Sharaf, S. M., & Refai, A. N. (2010). HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev, 11(1), 111-116. 

Abu-Rustum, N. R., Alektiar, K., Iasonos, A., Lev, G., Sonoda, Y., Aghajanian, C., . . . Barakat, R. R. (2006). The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol, 103(2), 714-718. doi:10.1016/j.ygyno.2006.03.055

Abu-Rustum, N. R., Chi, D. S., Sonoda, Y., DiClemente, M. J., Bekker, G., Gemignani, M., . . . Barakat, R. R. (2003). Transperitoneal laparoscopic pelvic and para-aortic lymph node dissection using the argon-beam coagulator and monopolar instruments: an 8-year study and description of technique. Gynecol Oncol, 89(3), 504-513. 

ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures. (2018). Obstet Gynecol, 131(6), e172-e189. doi:10.1097/aog.0000000000002670

Adami, H. O., Hsieh, C. C., Lambe, M., Trichopoulos, D., Leon, D., Persson, I., . . . Janson, P. O. (1994). Parity, age at first childbirth, and risk of ovarian cancer. Lancet, 344(8932), 1250-1254. 

Aebi, S., & Castiglione, M. (2009). Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 20 Suppl 4, 21-23. doi:10.1093/annonc/mdp117

Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., . . . Nycum, L. R. (2012). OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol, 30(17), 2039-2045. doi:10.1200/JCO.2012.42.0505

Akeson, M., Zetterqvist, B. M., Dahllof, K., Jakobsen, A. M., Brannstrom, M., & Horvath, G. (2008). Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. Int J Gynecol Cancer, 18(3), 453-459. doi:10.1111/j.1525-1438.2007.01051.x

Al Rawahi, T., Lopes, A. D., Bristow, R. E., Bryant, A., Elattar, A., Chattopadhyay, S., & Galaal, K. (2013). Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev(2), Cd008765. doi:10.1002/14651858.CD008765.pub3

Aletti, G. D., Dowdy, S. C., Gostout, B. S., Jones, M. B., Stanhope, C. R., Wilson, T. O., . . . Cliby, W. A. (2006). Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol, 107(1), 77-85. doi:10.1097/01.AOG.0000192407.04428.bb

Aletti, G. D., Santillan, A., Eisenhauer, E. L., Hu, J., Aletti, G., Podratz, K. C., . . . Cliby, W. A. (2007). A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol, 107(1), 99-106. doi:10.1016/j.ygyno.2007.05.032

Alphs, H. H., Zahurak, M. L., Bristow, R. E., & Diaz-Montes, T. P. (2006). Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol, 103(3), 1048-1053. doi:10.1016/j.ygyno.2006.06.019

Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., . . . Mitchell, G. (2012). BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol, 30(21), 2654-2663. doi:10.1200/jco.2011.39.8545

Amant, F., Halaska, M. J., Fumagalli, M., Dahl Steffensen, K., Lok, C., Van Calsteren, K., . . . Nulman, I. (2014). Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer, 24(3), 394-403. doi:10.1097/igc.0000000000000062

Amant, F., Van Calsteren, K., Halaska, M. J., Beijnen, J., Lagae, L., Hanssens, M., . . . du Bois, A. (2009). Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. Int J Gynecol Cancer, 19 Suppl 1, S1-12. doi:10.1111/IGC.0b013e3181a1d0ec

Amant, F., Van Calsteren, K., Halaska, M. J., Gziri, M. M., Hui, W., Lagae, L., . . . Ottevanger, P. B. (2012). Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol, 13(3), 256-264. doi:10.1016/S1470-2045(11)70363-1

Amato, A., & Pescatori, M. (2006). Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev(1), Cd005033. doi:10.1002/14651858.CD005033.pub2

Anchezar, J. P., Sardi, J., & Soderini, A. (2009). Long-term follow-up results of fertility sparing surgery in patients with epithelial ovarian cancer. J Surg Oncol, 100(1), 55-58. doi:10.1002/jso.21297

Andikyan, V., Kim, A., Gretz, H. F., 3rd, Zakashansky, K., Prasad-Hayes, M., Beddoe, A. M., . . . Chuang, L. (2018). Laparoscopic Assessment to Determine the Likelihood of Achieving Optimal Cytoreduction in Patients Undergoing Primary Debulking Surgery for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Am J Clin Oncol, 41(10), 938-942. doi:10.1097/coc.0000000000000413

Annon, J. (1976). The PLISSIT model: a proposed conceptual scheme for the behavioural treatment of sexual problems.  . J Sex Edu Ther., 1, 1-15. 

Anthoulakis, C., & Nikoloudis, N. (2014). Pelvic MRI as the "gold standard" in the subsequent evaluation of ultrasound-indeterminate adnexal lesions: a systematic review. Gynecol Oncol, 132(3), 661-668. doi:10.1016/j.ygyno.2013.10.022

Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., . . . Gynecologic Oncology, G. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med, 354(1), 34-43. doi:10.1056/NEJMoa052985

Ataseven, B., Grimm, C., Harter, P., Heitz, F., Traut, A., Prader, S., & du Bois, A. (2016). Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecol Oncol, 140(2), 215-220. doi:10.1016/j.ygyno.2015.12.007

Audette, C., & Waterman, J. (2010). The sexual health of women after gynecologic malignancy. J Midwifery Womens Health, 55(4), 357-362. doi:10.1016/j.jmwh.2009.10.016

Baandrup, L., Faber, M. T., Christensen, J., Jensen, A., Andersen, K. K., Friis, S., & Kjaer, S. K. (2013). Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand, 92(3), 245-255. doi:10.1111/aogs.12069

Bachmann, G., Bancroft, J., Braunstein, G., Burger, H., Davis, S., Dennerstein, L., . . . Princeton. (2002). Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril, 77(4), 660-665. 

Backman, M., Browall, M., Sundberg, C. J., & Wengstrom, Y. (2016). Experiencing health - Physical activity during adjuvant chemotherapy treatment for women with breast cancer. Eur J Oncol Nurs, 21, 160-167. doi:10.1016/j.ejon.2015.09.007

Baird, R. D., Tan, D. S., & Kaye, S. B. (2010). Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol, 7(10), 575-582. doi:10.1038/nrclinonc.2010.120

Bankhead, C. R., Collins, C., Stokes-Lampard, H., Rose, P., Wilson, S., Clements, A., . . . Austoker, J. (2008). Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG, 115(8), 1008-1014. doi:10.1111/j.1471-0528.2008.01772.x

Bankhead, C. R., Kehoe, S. T., & Austoker, J. (2005). Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG, 112(7), 857-865. doi:10.1111/j.1471-0528.2005.00572.x

Bass, B. P., Engel, K. B., Greytak, S. R., & Moore, H. M. (2014). A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? Arch Pathol Lab Med, 138(11), 1520-1530. doi:10.5858/arpa.2013-0691-RA

Basson, R. (2010). Sexual function of women with chronic illness and cancer. Womens Health (Lond Engl), 6(3), 407-429. doi:10.2217/whe.10.23

Bell, J., Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., . . . Gynecologic Oncology, G. (2006). Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 102(3), 432-439. doi:10.1016/j.ygyno.2006.06.013

Bell, K. A., Smith Sehdev, A. E., & Kurman, R. J. (2001). Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol, 25(4), 419-432. 

Bentivegna, E., Gouy, S., Maulard, A., Pautier, P., Leary, A., Colombo, N., & Morice, P. (2016). Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues. Ann Oncol, 27(11), 1994-2004. doi:10.1093/annonc/mdw311

Beral, V., Gaitskell, K., Hermon, C., Moser, K., Reeves, G., & Peto, R. (2015). Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet, 385(9980), 1835-1842. doi:10.1016/s0140-6736(14)61687-1

Beral, V., Million Women Study, C., Bull, D., Green, J., & Reeves, G. (2007). Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet, 369(9574), 1703-1710. doi:10.1016/S0140-6736(07)60534-0

Berek, J. S., Matulonis, U. A., Peen, U., Ghatage, P., Mahner, S., Redondo, A., . . . Mirza, M. R. (2018). Safety and dose modification for patients receiving niraparib. Ann Oncol, 29(8), 1784-1792. doi:10.1093/annonc/mdy181

Bernhard, L. M., Klebba, P. K., Gray, D. L., & Mutch, D. G. (1999). Predictors of persistence of adnexal masses in pregnancy. Obstet Gynecol, 93(4), 585-589. 

Bertelsen, K. (1990). Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol, 38(2), 203-209. 

Bertelsen, K., Jakobsen, A., Stroyer, J., Nielsen, K., Sandberg, E., Andersen, J. E., . . . et al. (1993). A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol, 49(1), 30-36. 

Berveiller, P., Veyrie, N., Rouzier, R., Carbonne, B., & Mir, O. (2011). Anti-cancer agents for breast cancer treatment during pregnancy. J Surg Oncol, 104(5), 560; author reply 559. doi:10.1002/jso.21951

Bige, O., Demir, A., Saygili, U., Gode, F., Uslu, T., & Koyuncuoglu, M. (2011). Frozen section diagnoses of 578 ovarian tumors made by pathologists with and without expertise on gynecologic pathology. Gynecol Oncol, 123(1), 43-46. doi:10.1016/j.ygyno.2011.06.030

Bijelic, L., Jonson, A., & Sugarbaker, P. H. (2007). Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol, 18(12), 1943-1950. doi:10.1093/annonc/mdm137

Billfeldt, N. K., Borgfeldt, C., Lindkvist, H., Stjerndahl, J. H., & Ankardal, M. (2018). A Swedish population-based evaluation of benign hysterectomy, comparing minimally invasive and abdominal surgery. Eur J Obstet Gynecol Reprod Biol, 222, 113-118. doi:10.1016/j.ejogrb.2018.01.019

Bloom, J. R., Petersen, D. M., & Kang, S. H. (2007). Multi-dimensional quality of life among long-term (5+ years) adult cancer survivors. Psychooncology, 16(8), 691-706. doi:10.1002/pon.1208

Bodurka, D. C., & Sun, C. C. (2006). Sexual function after gynecologic cancer. Obstet Gynecol Clin North Am, 33(4), 621-630, ix. doi:10.1016/j.ogc.2006.09.006

Boere, I., Lok, C., Vandenbroucke, T., & Amant, F. (2017). Cancer in pregnancy: safety and efficacy of systemic therapies. Curr Opin Oncol, 29(5), 328-334. doi:10.1097/cco.0000000000000386

Bolton, K. L., Chenevix-Trench, G., Goh, C., Sadetzki, S., Ramus, S. J., Karlan, B. Y., . . . Cancer Genome Atlas Research, N. (2012). Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA, 307(4), 382-390. doi:10.1001/jama.2012.20

Bookman, M. A., Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M., . . . Roth, L. M. (2009). Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol, 27(9), 1419-1425. doi:10.1200/JCO.2008.19.1684

Borgfeldt, C., Iosif, C., & Masback, A. (2007). Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. Eur J Obstet Gynecol Reprod Biol, 134(1), 110-114. doi:10.1016/j.ejogrb.2006.05.037

Bowtell, D. D. (2010). The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer, 10(11), 803-808. doi:10.1038/nrc2946

Bradley, K. A., Rubinsky, A. D., Sun, H., Bryson, C. L., Bishop, M. J., Blough, D. K., . . . Kivlahan, D. R. (2011). Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med, 26(2), 162-169. doi:10.1007/s11606-010-1475-x

Bristow, R. E., Karlan, B. Y., & Chi, D. S. (2011). Surgery for ovarian cancer [Elektronisk resurs] : principles and practice. New York: Informa Healthcare.

Bristow, R. E., Montz, F. J., Lagasse, L. D., Leuchter, R. S., & Karlan, B. Y. (1999). Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol, 72(3), 278-287. doi:10.1006/gyno.1998.5145

Bristow, R. E., Santillan, A., Diaz-Montes, T. P., Gardner, G. J., Giuntoli, R. L., 2nd, Meisner, B. C., . . . Armstrong, D. K. (2007). Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer, 109(8), 1513-1522. doi:10.1002/cncr.22561

Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 20(5), 1248-1259. 

Brohet, R. M., Goldgar, D. E., Easton, D. F., Antoniou, A. C., Andrieu, N., Chang-Claude, J., . . . Rookus, M. A. (2007). Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol, 25(25), 3831-3836. doi:10.1200/JCO.2007.11.1179

Brown, J., & Frumovitz, M. (2014). Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep, 16(6), 389. doi:10.1007/s11912-014-0389-x

Brynhilsen, J., & Wikström, I. (2014). Preventivmedel och cancer. Information från Läkemedelsverket 2: 2014. . Retrieved from www.nccn.org/professionals/physician_gls/f_guidelines.asp

Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., . . . Gynecologic Oncology, G. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med, 365(26), 2473-2483. doi:10.1056/NEJMoa1104390

Buys, S. S., Partridge, E., Black, A., Johnson, C. C., Lamerato, L., Isaacs, C., . . . Berg, C. D. (2011). Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA, 305(22), 2295-2303. doi:10.1001/jama.2011.766

Cadron, I., Leunen, K., Van Gorp, T., Amant, F., Neven, P., & Vergote, I. (2007). Management of borderline ovarian neoplasms. J Clin Oncol, 25(20), 2928-2937. doi:10.1200/JCO.2007.10.8076

Caldwell, J., Edriss, H., & Nugent, K. (2018). Chronic peritoneal indwelling catheters for the management of malignant and nonmalignant ascites. Proc (Bayl Univ Med Cent), 31(3), 297-302. doi:10.1080/08998280.2018.1461525

Callahan, M. J., Crum, C. P., Medeiros, F., Kindelberger, D. W., Elvin, J. A., Garber, J. E., . . . Muto, M. G. (2007). Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol, 25(25), 3985-3990. doi:10.1200/JCO.2007.12.2622

Calsteren, K. V., Verbesselt, R., Devlieger, R., De Catte, L., Chai, D. C., Van Bree, R., . . . Amant, F. (2010). Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. Int J Gynecol Cancer, 20(9), 1456-1464. doi:10.1111/IGC.0b013e3181fb18c8

Cancerincidens i Sverige 2014 - Nya diagnosticerade cancerfall år 2014. Retrieved from https://www.socialstyrelsen.se/publikationer2015/2015-12-26

Carmack Taylor, C. L., Basen-Engquist, K., Shinn, E. H., & Bodurka, D. C. (2004). Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol, 22(5), 881-889. doi:10.1200/JCO.2004.08.150

Carney, M. E., Lancaster, J. M., Ford, C., Tsodikov, A., & Wiggins, C. L. (2002). A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol, 84(1), 36-42. doi:10.1006/gyno.2001.6460

Cascales Campos, P., Gil, J., & Parrilla, P. (2014). Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer. Eur J Surg Oncol, 40(8), 970-975. doi:10.1016/j.ejso.2013.08.013

Casey, M. J., Synder, C., Bewtra, C., Narod, S. A., Watson, P., & Lynch, H. T. (2005). Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol, 97(2), 457-467. doi:10.1016/j.ygyno.2005.01.039

Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., . . . Monk, B. J. (2016). Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med, 374(8), 738-748. doi:10.1056/NEJMoa1505067

Chan, J. K., Tian, C., Fleming, G. F., Monk, B. J., Herzog, T. J., Kapp, D. S., & Bell, J. (2010). The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol, 116(3), 301-306. doi:10.1016/j.ygyno.2009.10.073

Charbonneau, B., Block, M. S., Bamlet, W. R., Vierkant, R. A., Kalli, K. R., Fogarty, Z., . . . Goode, E. L. (2014). Risk of ovarian cancer and the NF-kappaB pathway: genetic association with IL1A and TNFSF10. Cancer Res, 74(3), 852-861. doi:10.1158/0008-5472.CAN-13-1051

Cheng, A., Li, M., Kanis, M. J., Xu, Y., Zhang, Q., Cui, B., . . . Kong, B. (2017). Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis. Gynecol Oncol, 144(1), 215-222. doi:10.1016/j.ygyno.2016.10.041

Chi, D. S., Eisenhauer, E. L., Lang, J., Huh, J., Haddad, L., Abu-Rustum, N. R., . . . Barakat, R. R. (2006). What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol, 103(2), 559-564. doi:10.1016/j.ygyno.2006.03.051

Chi, D. S., Zivanovic, O., Levinson, K. L., Kolev, V., Huh, J., Dottino, J., . . . Barakat, R. R. (2010). The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol, 119(1), 38-42. doi:10.1016/j.ygyno.2010.05.031

Chiaffarino, F., Pelucchi, C., Negri, E., Parazzini, F., Franceschi, S., Talamini, R., . . . La Vecchia, C. (2005). Breastfeeding and the risk of epithelial ovarian cancer in an Italian population. Gynecol Oncol, 98(2), 304-308. doi:10.1016/j.ygyno.2005.05.006

Childers, J. M., Brzechffa, P. R., & Surwit, E. A. (1993). Laparoscopy using the left upper quadrant as the primary trocar site. Gynecol Oncol, 50(2), 221-225. doi:10.1006/gyno.1993.1196

Chiu, H. Y., Shyu, Y. K., Chang, P. C., & Tsai, P. S. (2016). Effects of Acupuncture on Menopause-Related Symptoms in Breast Cancer Survivors: A Meta-analysis of Randomized Controlled Trials. Cancer Nurs, 39(3), 228-237. doi:10.1097/ncc.0000000000000278

Cibula, D., Zikan, M., Dusek, L., & Majek, O. (2011). Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther, 11(8), 1197-1207. doi:10.1586/era.11.38

Clamp, A. R., McNeish, I., & Dean, A. (2017). ICON8: a GCIG phase III randomized trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression-free survival (PFS) analysis. . Paper presented at the ESMO 2017 Congress. , Madrid, Spain. 

Clarke, T., Galaal, K., Bryant, A., & Naik, R. (2014). Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database Syst Rev(9), Cd006119. doi:10.1002/14651858.CD006119.pub3

Cohen-Kerem, R., Railton, C., Oren, D., Lishner, M., & Koren, G. (2005). Pregnancy outcome following non-obstetric surgical intervention. Am J Surg, 190(3), 467-473. doi:10.1016/j.amjsurg.2005.03.033

Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., . . . Mannel, R. S. (2017). Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 18(6), 779-791. doi:10.1016/s1470-2045(17)30279-6

Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., . . . Ledermann, J. A. (2017). Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 390(10106), 1949-1961. doi:10.1016/s0140-6736(17)32440-6

Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., Cloven, N. G., Oaknin, A., DiSilvestro, P. A., Morgan, M. A., Nam, J. H., Leath, C. A., 3rd, Nicum, S., Hagemann, A. R., Littell, R. D., Cella, D., … Bookman, M. A. (2019). Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. The New England journal of medicine381(25), 2403–2415. https://doi.org/10.1056/NEJMoa1909707

Collaborative Group on Epidemiological Studies of Ovarian, C., Beral, V., Doll, R., Hermon, C., Peto, R., & Reeves, G. (2008). Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet, 371(9609), 303-314. doi:10.1016/S0140-6736(08)60167-1

Collins, I. M., Roberts-Thomson, R., Faulkner, D., Rischin, D., Friedlander, M., & Mileshkin, L. (2011). Carboplatin dosing in ovarian cancer: problems and pitfalls. Int J Gynecol Cancer, 21(7), 1213-1218. doi:10.1097/IGC.0b013e31822127ad

Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J., . . . Sessa, C. (2016). ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer, 26(1), 2-30. doi:10.1097/igc.0000000000000609

Colomer, A. T., Jimenez, A. M., & Bover Barcelo, M. I. (2008). Laparoscopic treatment and staging of early ovarian cancer. J Minim Invasive Gynecol, 15(4), 414-419. doi:10.1016/j.jmig.2008.04.002

Corn, B. W., Lanciano, R. M., Boente, M., Hunter, W. M., Ladazack, J., & Ozols, R. F. (1994). Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure. Cancer, 74(11), 2979-2983. 

Cosyns, S., De Sutter, P., Tournaye, H., & Polyzos, N. P. (2016). Necessity of appendectomy for mucinous borderline ovarian tumors. Systematic review. Arch Gynecol Obstet, 294(6), 1283-1289. doi:10.1007/s00404-016-4174-y

Cox, A., Bull, E., Cockle-Hearne, J., Knibb, W., Potter, C., & Faithfull, S. (2008). Nurse led telephone follow up in ovarian cancer: a psychosocial perspective. Eur J Oncol Nurs, 12(5), 412-417. doi:10.1016/j.ejon.2008.06.002

Dahm-Kahler, P., Palmqvist, C., Staf, C., Holmberg, E., & Johannesson, L. (2016). Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. Gynecol Oncol, 142(2), 211-216. doi:10.1016/j.ygyno.2016.05.025

Daley, A. J., Thomas, A., Roalfe, A. K., Stokes-Lampard, H., Coleman, S., Rees, M., . . . MacArthur, C. (2015). The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial. BJOG, 122(4), 565-575. doi:10.1111/1471-0528.13193

Danforth, K. N., Tworoger, S. S., Hecht, J. L., Rosner, B. A., Colditz, G. A., & Hankinson, S. E. (2007). Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer Causes Control, 18(5), 517-523. doi:10.1007/s10552-007-0130-2

Dashti, S. G., Chau, R., Ouakrim, D. A., Buchanan, D. D., Clendenning, M., Young, J. P., . . . Win, A. K. (2015). Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome. JAMA, 314(1), 61-71. doi:10.1001/jama.2015.6789

Davis, S. R. (2013). Androgen use for low sexual desire in midlife women. Menopause, 20(7), 795-797. doi:10.1097/GME.0b013e31828b2fd5

Davison, S. L., Bell, R., Donath, S., Montalto, J. G., & Davis, S. R. (2005). Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab, 90(7), 3847-3853. doi:10.1210/jc.2005-0212

de Groot, J. J., Ament, S. M., Maessen, J. M., Dejong, C. H., Kleijnen, J. M., & Slangen, B. F. (2016). Enhanced recovery pathways in abdominal gynecologic surgery: a systematic review and meta-analysis. Acta Obstet Gynecol Scand, 95(4), 382-395. doi:10.1111/aogs.12831

de Haan, J., Verheecke, M., Van Calsteren, K., Van Calster, B., Shmakov, R. G., Mhallem Gziri, M., . . . Amant, F. (2018). Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol, 19(3), 337-346. doi:10.1016/s1470-2045(18)30059-7

Demeestere, I., Brice, P., Peccatori, F. A., Kentos, A., Dupuis, J., Zachee, P., . . . Englert, Y. (2016). No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. J Clin Oncol, 34(22), 2568-2574. doi:10.1200/jco.2015.65.8864

DeVita, V. T., Jr. (1983). The James Ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer, 51(7), 1209-1220. 

Dockery, L. E., Tew, W. P., Ding, K., & Moore, K. N. (2017). Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecol Oncol, 147(3), 509-513. doi:10.1016/j.ygyno.2017.10.007

Dodin, S., Blanchet, C., Marc, I., Ernst, E., Wu, T., Vaillancourt, C., . . . Maunsell, E. (2013). Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev, 7, CD007410. doi:10.1002/14651858.CD007410.pub2

Dolan, E. A. (2011). Malignant bowel obstruction: a review of current treatment strategies. Am J Hosp Palliat Care, 28(8), 576-582. doi:10.1177/1049909111406706

Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., . . . Rebbeck, T. R. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA, 304(9), 967-975. doi:10.1001/jama.2010.1237

du Bois, A., Ewald-Riegler, N., de Gregorio, N., Reuss, A., Mahner, S., Fotopoulou, C., . . . Arbeitsgmeinschaft Gynakologische Onkologie Study, G. (2013). Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer, 49(8), 1905-1914. doi:10.1016/j.ejca.2013.01.035

du Bois, A., Ewald-Riegler, N., du Bois, O., & Harter, P. (2009). Borderline tumors of the ovary – a systematic review [German]. . Geburtsh Frauenheilk, , 807-833. 

du Bois, A., Floquet, A., Kim, J. W., Rau, J., del Campo, J. M., Friedlander, M., . . . Harter, P. (2014). Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol, 32(30), 3374-3382. doi:10.1200/JCO.2014.55.7348

du Bois, A., Heitz, F., & Harter, P. (2013). Fertility-sparing surgery in ovarian cancer: a systematic review. Onkologie, 36(7-8), 436-443. doi:10.1159/000353598

du Bois, A., Herrstedt, J., Hardy-Bessard, A. C., Muller, H. H., Harter, P., Kristensen, G., . . . Sehouli, J. (2010). Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol, 28(27), 4162-4169. doi:10.1200/JCO.2009.27.4696

du Bois, A., Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., . . . Harter, P. (2016). Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol, 17(1), 78-89. doi:10.1016/s1470-2045(15)00366-6

du Bois, A., Luck, H. J., Meier, W., Adams, H. P., Mobus, V., Costa, S., . . . Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study, G. (2003). A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst, 95(17), 1320-1329. 

du Bois, A., Marth, C., Pfisterer, J., Harter, P., Hilpert, F., Zeimet, A. G., & Sehouli, J. (2012). Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer. Int J Gynecol Cancer, 22(2), 182-185. doi:10.1097/IGC.0b013e31821d419a

du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., & Pfisterer, J. (2009). Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer, 115(6), 1234-1244. doi:10.1002/cncr.24149

du Bois, A., Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., . . . Groupe d'Investigateurs Nationaux pour l'Etude des Cancers, O. (2006). Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol, 24(7), 1127-1135. doi:10.1200/JCO.2005.03.2938

Eeles, R. A., Tan, S., Wiltshaw, E., Fryatt, I., A'Hern, R. P., Shepherd, J. H., . . . Chilvers, C. E. (1991). Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ, 302(6771), 259-262. 

Einhorn, N. (1999). Kemoterapi och effekter på gonaderna;  Hormonell ovarialstimulering för infertilitetsbehandling och risk för ovarialcancer. Högberg T., Larsson B (red.). Cancer, graviditet och fertilitet. (ARG-rapport nr 41. ). Retrieved from 

Eisen, A., Lubinski, J., Gronwald, J., Moller, P., Lynch, H. T., Klijn, J., . . . Narod, S. A. (2008). Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst, 100(19), 1361-1367. doi:10.1093/jnci/djn313

Eisen, A., Lubinski, J., Klijn, J., Moller, P., Lynch, H. T., Offit, K., . . . Narod, S. A. (2005). Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol, 23(30), 7491-7496. doi:10.1200/JCO.2004.00.7138

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., . . . Verweij, J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45(2), 228-247. doi:10.1016/j.ejca.2008.10.026

Eisenkop, S. M., Friedman, R. L., & Spirtos, N. M. (2000). The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer, 88(1), 144-153. 

Eisenkop, S. M., Friedman, R. L., & Wang, H. J. (1998). Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol, 69(2), 103-108. doi:10.1006/gyno.1998.4955

Eisenkop, S. M., Spirtos, N. M., Montag, T. W., Nalick, R. H., & Wang, H. J. (1992). The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol, 47(2), 203-209. 

Elgindy, E., Sibai, H., Abdelghani, A., & Mostafa, M. (2015). Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis. Obstet Gynecol, 126(1), 187-195. doi:10.1097/aog.0000000000000905

En nationell cancerstrategi för framtiden. SOU 2009:11. Regeringskansliet Retrieved from https://www.regeringen.se/rattsliga-dokument/statens-offentliga-utredningar/2009/02/sou-200911/

Engelen, M. J., Kos, H. E., Willemse, P. H., Aalders, J. G., de Vries, E. G., Schaapveld, M., . . . van der Zee, A. G. (2006). Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer, 106(3), 589-598. doi:10.1002/cncr.21616

Eras / Guidelines / List of Guidelines Retrieved from http://erassociety.org/guidelines/list-of-guidelines/

Fadare, O. (2009). Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors). Int J Gynecol Cancer, 19(1), 103-108. doi:10.1111/IGC.0b013e3181991a49

Falcetta, F. S., Lawrie, T. A., Medeiros, L. R., da Rosa, M. I., Edelweiss, M. I., Stein, A. T., . . . Rosa, D. D. (2016). Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Cochrane Database Syst Rev, 10, Cd005344. doi:10.1002/14651858.CD005344.pub4

Falconer, H., Yin, L., Gronberg, H., & Altman, D. (2015). Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst, 107(2). doi:10.1093/jnci/dju410

Faluyi, O., Mackean, M., Gourley, C., Bryant, A., & Dickinson, H. O. (2010). Interventions for the treatment of borderline ovarian tumours. Cochrane Database Syst Rev(9), CD007696. doi:10.1002/14651858.CD007696.pub2

Fauvet, R., Brzakowski, M., Morice, P., Resch, B., Marret, H., Graesslin, O., & Darai, E. (2012). Borderline ovarian tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: results of a French multicenter study. Ann Oncol, 23(6), 1481-1487. doi:10.1093/annonc/mdr452

Ferrandina, G., Ludovisi, M., Lorusso, D., Pignata, S., Breda, E., Savarese, A., . . . Scambia, G. (2008). Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol, 26(6), 890-896. doi:10.1200/JCO.2007.13.6606

Finch, A. P., Lubinski, J., Moller, P., Singer, C. F., Karlan, B., Senter, L., . . . Narod, S. A. (2014). Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol, 32(15), 1547-1553. doi:10.1200/JCO.2013.53.2820

Fischerova, D., & Burgetova, A. (2014). Imaging techniques for the evaluation of ovarian cancer. Best Pract Res Clin Obstet Gynaecol, 28(5), 697-720. doi:10.1016/j.bpobgyn.2014.04.006

Fischerova, D., Cibula, D., Dundr, P., Zikan, M., Calda, P., Freitag, P., & Slama, J. (2008). Ultrasound-guided tru-cut biopsy in the management of advanced abdomino-pelvic tumors. Int J Gynecol Cancer, 18(4), 833-837. doi:10.1111/j.1525-1438.2007.01015.x

Fischerova, D., Zikan, M., Dundr, P., & Cibula, D. (2012). Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist, 17(12), 1515-1533. doi:10.1634/theoncologist.2012-0139

Fleming, C. A., Heneghan, H. M., O'Brien, D., McCartan, D. P., McDermott, E. W., & Prichard, R. S. (2018). Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br J Surg, 105(9), 1098-1106. doi:10.1002/bjs.10899

Forstner, R., Sala, E., Kinkel, K., & Spencer, J. A. (2010). ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol, 20(12), 2773-2780. doi:10.1007/s00330-010-1886-4

Forstner, R., Thomassin-Naggara, I., Cunha, T. M., Kinkel, K., Masselli, G., Kubik-Huch, R., . . . Rockall, A. (2017). ESUR recommendations for MR imaging of the sonographically indeterminate adnexal mass: an update. Eur Radiol, 27(6), 2248-2257. doi:10.1007/s00330-016-4600-3

Fotopoulou, C., Hall, M., Cruickshank, D., Gabra, H., Ganesan, R., Hughes, C., . . . Sundar, S. (2017). British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol, 213, 123-139. doi:10.1016/j.ejogrb.2017.04.016

Froyman, W., Landolfo, C., De Cock, B., Wynants, L., Sladkevicius, P., Testa, A. C., . . . Timmerman, D. (2019). Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. Lancet Oncol, 20(3), 448-458. doi:10.1016/s1470-2045(18)30837-4

Fruscio, R., de Haan, J., Van Calsteren, K., Verheecke, M., Mhallem, M., & Amant, F. (2017). Ovarian cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol, 41, 108-117. doi:10.1016/j.bpobgyn.2016.09.013

Gadducci, A., Fuso, L., Cosio, S., Landoni, F., Maggino, T., Perotto, S., . . . Zola, P. (2009). Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study. Int J Gynecol Cancer, 19(3), 367-374. doi:10.1111/IGC.0b013e3181a1cc02

Gaitskell, K., Martinek, I., Bryant, A., Kehoe, S., Nicum, S., & Morrison, J. (2011). Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev(9), CD007930. doi:10.1002/14651858.CD007930.pub2

Gatcliffe, T. A., & Coleman, R. L. (2008). Tumor board: more than treatment planning--a 1-year prospective survey. J Cancer Educ, 23(4), 235-237. doi:10.1080/08858190802189014

Geomini, P., Kruitwagen, R., Bremer, G. L., Cnossen, J., & Mol, B. W. (2009). The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol, 113(2 Pt 1), 384-394. doi:10.1097/AOG.0b013e318195ad17

Gershenson, D. M., Sun, C. C., Iyer, R. B., Malpica, A. L., Kavanagh, J. J., Bodurka, D. C., . . . Deavers, M. (2012). Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol, 125(3), 661-666. doi:10.1016/j.ygyno.2012.02.037

Geurts, S. M., van Altena, A. M., de Vegt, F., Tjan-Heijnen, V. C., Massuger, L. F., van Dijck, J. A., & Verbeek, A. L. (2011). No supportive evidence for clinical benefit of routine follow-up in ovarian cancer: a Dutch multicenter study. Int J Gynecol Cancer, 21(4), 647-653. doi:10.1097/IGC.0b013e318212b87d

Giede, K. C., Kieser, K., Dodge, J., & Rosen, B. (2005). Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol, 99(2), 447-461. doi:10.1016/j.ygyno.2005.07.008

Giuntoli, R. L., 2nd, Vang, R. S., & Bristow, R. E. (2006). Evaluation and management of adnexal masses during pregnancy. Clin Obstet Gynecol, 49(3), 492-505. 

Goff, B. A., Mandel, L., Muntz, H. G., & Melancon, C. H. (2000). Ovarian carcinoma diagnosis. Cancer, 89(10), 2068-2075. 

González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., Baumann, K., Jardon, K., Redondo, A., Moore, R. G., Vulsteke, C., O'Cearbhaill, R. E., Lund, B., Backes, F., Barretina-Ginesta, P., Haggerty, A. F., … PRIMA/ENGOT-OV26/GOG-3012 Investigators (2019). Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. The New England journal of medicine381(25), 2391–2402. https://doi.org/10.1056/NEJMoa1910962

Goodenberger, M. L., Thomas, B. C., Riegert-Johnson, D., Boland, C. R., Plon, S. E., Clendenning, M., . . . Lindor, N. M. (2016). PMS2 monoallelic mutation carriers: the known unknown. Genet Med, 18(1), 13-19. doi:10.1038/gim.2015.27

Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001). Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol, 19(14), 3312-3322. 

Gore, M., Mainwaring, P., A'Hern, R., MacFarlane, V., Slevin, M., Harper, P., . . . Shepherd, J. (1998). Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol, 16(7), 2426-2434. 

Gotlieb, W. H., Chetrit, A., Menczer, J., Hirsh-Yechezkel, G., Lubin, F., Friedman, E., . . . Ben-Baruch, G. (2005). Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol, 97(3), 780-783. doi:10.1016/j.ygyno.2005.02.022

Grabowski, J. P., Harter, P., Heitz, F., Pujade-Lauraine, E., Reuss, A., Kristensen, G., . . . du Bois, A. (2016). Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol, 140(3), 457-462. doi:10.1016/j.ygyno.2016.01.022

Greco, M., Capretti, G., Beretta, L., Gemma, M., Pecorelli, N., & Braga, M. (2014). Enhanced recovery program in colorectal surgery: a meta-analysis of randomized controlled trials. World J Surg, 38(6), 1531-1541. doi:10.1007/s00268-013-2416-8

Greer, H. O., Frederick, P. J., Falls, N. M., Tapley, E. B., Samples, K. L., Kimball, K. J., . . . Straughn, J. M., Jr. (2010). Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies. Int J Gynecol Cancer, 20(8), 1321-1325. doi:10.1111/IGC.0b013e3181f5871e

Greiser, C. M., Greiser, E. M., & Doren, M. (2007). Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update, 13(5), 453-463. doi:10.1093/humupd/dmm012

Griffin, N., Grant, L. A., & Sala, E. (2010). Adnexal masses: characterization and imaging strategies. Semin Ultrasound CT MR, 31(5), 330-346. doi:10.1053/j.sult.2010.07.002

Guidozzi, F., & Daponte, A. (1999). Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer, 86(6), 1013-1018. 

Gustafsson, U. O., Scott, M. J., Hubner, M., Nygren, J., Demartines, N., Francis, N., . . . Ljungqvist, O. (2019). Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS((R))) Society Recommendations: 2018. World J Surg, 43(3), 659-695. doi:10.1007/s00268-018-4844-y

Gustafsson, U. O., Scott, M. J., Schwenk, W., Demartines, N., Roulin, D., Francis, N., . . . Ljungqvist, O. (2013). Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS((R))) Society recommendations. World J Surg, 37(2), 259-284. doi:10.1007/s00268-012-1772-0

Hakes, T. B., Chalas, E., Hoskins, W. J., Jones, W. B., Markman, M., Rubin, S. C., . . . Lewis, J. L., Jr. (1992). Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol, 45(3), 284-289. 

Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., . . . Konishi, I. (2015). Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol, 33(34), 4015-4022. doi:10.1200/jco.2015.62.3397

Han, S. N., Lotgerink, A., Gziri, M. M., Van Calsteren, K., Hanssens, M., & Amant, F. (2012). Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Med, 10, 86. doi:10.1186/1741-7015-10-86

Hanai, A., Ishiguro, H., Sozu, T., Tsuda, M., Yano, I., Nakagawa, T., . . . Tsuboyama, T. (2018). Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. J Natl Cancer Inst, 110(2), 141-148. doi:10.1093/jnci/djx178

Harter, P., du Bois, A., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., . . . Sehouli, J. (2006). Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol, 13(12), 1702-1710. doi:10.1245/s10434-006-9058-0

Harter, P., Sehouli, J., Lorusso, D., Reuss, A., Vergote, I., Marth, C., . . . Bois, A. D. (2017). LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial. 35(15_suppl), 5500-5500. doi:10.1200/JCO.2017.35.15_suppl.5500

Harter, P., Sehouli, J., Reuss, A., Hasenburg, A., Scambia, G., Cibula, D., . . . du Bois, A. (2011). Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer, 21(2), 289-295. doi:10.1097/IGC.0b013e31820aaafd

Hauptmann, S., Friedrich, K., Redline, R., & Avril, S. (2017). Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch, 470(2), 125-142. doi:10.1007/s00428-016-2040-8

Havrilesky, L. J., Gierisch, J. M., Moorman, P. G., Coeytaux, R. R., Urrutia, R. P., Lowery, W. J., . . . Myers, E. R. (2013). Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep)(212), 1-514. 

Heatley, M. K. (2012). A systematic review of papers examining the use of intraoperative frozen section in predicting the final diagnosis of ovarian lesions. Int J Gynecol Pathol, 31(2), 111-115. doi:10.1097/PGP.0b013e318226043b

Heitz, F., Harter, P., Avall-Lundqvist, E., Reuss, A., Pautier, P., Cormio, G., . . . du Bois, A. (2019). Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. Gynecol Oncol, 152(2), 235-242. doi:10.1016/j.ygyno.2018.11.008

Henderson, J. T., Webber, E. M., & Sawaya, G. F. (2018). Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 319(6), 595-606. doi:10.1001/jama.2017.21421

Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., . . . American Society of Clinical, O. (2014). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 32(18), 1941-1967. doi:10.1200/JCO.2013.54.0914

Hope, J. M., & Pothuri, B. (2013). The role of palliative surgery in gynecologic cancer cases. Oncologist, 18(1), 73-79. doi:10.1634/theoncologist.2012-0328

Horvath, L. E., Yordan, E., Malhotra, D., Leyva, I., Bortel, K., Schalk, D., . . . Huml, J. (2010). Multidisciplinary care in the oncology setting: historical perspective and data from lung and gynecology multidisciplinary clinics. J Oncol Pract, 6(6), e21-26. doi:10.1200/JOP.2010.000073

Hoskins, P., Vergote, I., Cervantes, A., Tu, D., Stuart, G., Zola, P., . . . Eisenhauer, E. A. (2010). Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst, 102(20), 1547-1556. doi:10.1093/jnci/djq362

Huhtinen, K., Suvitie, P., Hiissa, J., Junnila, J., Huvila, J., Kujari, H., . . . Perheentupa, A. (2009). Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer, 100(8), 1315-1319. doi:10.1038/sj.bjc.6605011

Hunn, J., & Rodriguez, G. C. (2012). Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol, 55(1), 3-23. doi:10.1097/GRF.0b013e31824b4611

Ibeanu, O., Modesitt, S. C., Ducie, J., von Gruenigen, V., Agueh, M., & Fader, A. N. (2011). Hormone replacement therapy in gynecologic cancer survivors: why not? Gynecol Oncol, 122(2), 447-454. doi:10.1016/j.ygyno.2011.03.012

Iglesias, D. A., & Ramirez, P. T. (2011). Role of minimally invasive surgery in staging of ovarian cancer. Curr Treat Options Oncol, 12(3), 217-229. doi:10.1007/s11864-011-0155-3

Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., . . . Gandini, S. (2010). Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer, 46(12), 2275-2284. doi:10.1016/j.ejca.2010.04.018

Iwakawa, M., Noda, S., Yamada, S., Yamamoto, N., Miyazawa, Y., Yamazaki, H., . . . Imai, T. (2006). Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast Cancer, 13(3), 300-307. 

Jaaback, K., Johnson, N., & Lawrie, T. A. (2011). Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev(11), CD005340. doi:10.1002/14651858.CD005340.pub3

Jacobs, I., Oram, D., Fairbanks, J., Turner, J., Frost, C., & Grudzinskas, J. G. (1990). A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol, 97(10), 922-929. 

Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., . . . Skates, S. J. (2016). Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, 387(10022), 945-956. doi:10.1016/s0140-6736(15)01224-6

Jagsi, R., Griffith, K. A., Koelling, T., Roberts, R., & Pierce, L. J. (2007). Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, 109(4), 650-657. doi:10.1002/cncr.22452

Jakobsen, A., Bertelsen, K., Andersen, J. E., Havsteen, H., Jakobsen, P., Moeller, K. A., . . . Stroeyer, I. (1997). Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol, 15(1), 193-198. 

Janda, M., Youlden, D. R., Baade, P. D., Jackson, D., & Obermair, A. (2008). Elderly patients with stage III or IV ovarian cancer: should they receive standard care? Int J Gynecol Cancer, 18(5), 896-907. doi:10.1111/j.1525-1438.2007.01122.x

Janelsins, M. C., Kohli, S., Mohile, S. G., Usuki, K., Ahles, T. A., & Morrow, G. R. (2011). An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol, 38(3), 431-438. doi:10.1053/j.seminoncol.2011.03.014

Jansen, F. W., Kolkman, W., Bakkum, E. A., de Kroon, C. D., Trimbos-Kemper, T. C., & Trimbos, J. B. (2004). Complications of laparoscopy: an inquiry about closed- versus open-entry technique. Am J Obstet Gynecol, 190(3), 634-638. doi:10.1016/j.ajog.2003.09.035

Jareid, M., Thalabard, J. C., Aarflot, M., Bovelstad, H. M., Lund, E., & Braaten, T. (2018). Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol, 149(1), 127-132. doi:10.1016/j.ygyno.2018.02.006

Jayde, V., Boughton, M., & Blomfield, P. (2013). The experience of chemotherapy-induced alopecia for Australian women with ovarian cancer. Eur J Cancer Care (Engl), 22(4), 503-512. doi:10.1111/ecc.12056

Jensen, A., Sharif, H., Olsen, J. H., & Kjaer, S. K. (2008). Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol, 168(1), 49-57. doi:10.1093/aje/kwn094

Jordan, S. J., Cushing-Haugen, K. L., Wicklund, K. G., Doherty, J. A., & Rossing, M. A. (2012). Breast-feeding and risk of epithelial ovarian cancer. Cancer Causes Control, 23(6), 919-927. doi:10.1007/s10552-012-9963-4

Jordan, S. J., Whiteman, D. C., Purdie, D. M., Green, A. C., & Webb, P. M. (2006). Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol, 103(3), 1122-1129. doi:10.1016/j.ygyno.2006.08.012

Jung, U. S., Lee, J. H., Kyung, M. S., & Choi, J. S. (2009). Feasibility and efficacy of laparoscopic management of ovarian cancer. J Obstet Gynaecol Res, 35(1), 113-118. doi:10.1111/j.1447-0756.2008.00830.x

Junor, E. J., Hole, D. J., McNulty, L., Mason, M., & Young, J. (1999). Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol, 106(11), 1130-1136. 

Kajiyama, H., Shibata, K., Mizuno, M., Umezu, T., Suzuki, S., Nawa, A., . . . Kikkawa, F. (2011). Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer, 105(9), 1288-1294. doi:10.1038/bjc.2011.394

Kalapotharakos, G., Hogberg, T., Bergfeldt, K., & Borgfeldt, C. (2016). Long-term survival in women with borderline ovarian tumors: a population-based survey of borderline ovarian tumors in Sweden 1960-2007. Acta Obstet Gynecol Scand, 95(4), 473-479. doi:10.1111/aogs.12846

Kaldawy, A., Segev, Y., Lavie, O., Auslender, R., Sopik, V., & Narod, S. A. (2016). Low-grade serous ovarian cancer: A review. Gynecol Oncol, 143(2), 433-438. doi:10.1016/j.ygyno.2016.08.320

Kalogera, E., Dowdy, S. C., Mariani, A., Aletti, G., Bakkum-Gamez, J. N., & Cliby, W. A. (2012). Utility of closed suction pelvic drains at time of large bowel resection for ovarian cancer. Gynecol Oncol, 126(3), 391-396. doi:10.1016/j.ygyno.2012.05.021

Karam, A., Ledermann, J. A., Kim, J. W., Sehouli, J., Lu, K., Gourley, C., . . . Ochiai, K. (2017). Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol, 28(4), 711-717. doi:10.1093/annonc/mdx011

Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., . . . Japanese Gynecologic Oncology, G. (2013). Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol, 14(10), 1020-1026. doi:10.1016/S1470-2045(13)70363-2

Kaufman, E. L., Jacobson, J. S., Hershman, D. L., Desai, M., & Neugut, A. I. (2008). Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol, 26(3), 392-398. doi:10.1200/jco.2007.13.3033

Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., . . . Kaufman, B. (2012). Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol, 30(4), 372-379. doi:10.1200/JCO.2011.36.9215

Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., . . . Swart, A. M. (2015). Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet, 386(9990), 249-257. doi:10.1016/s0140-6736(14)62223-6

Keshaviah, A., Dellapasqua, S., Rotmensz, N., Lindtner, J., Crivellari, D., Collins, J., . . . Goldhirsch, A. (2007). CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol, 18(4), 701-708. doi:10.1093/annonc/mdl492

Keulers, B. J., Scheltinga, M. R., Houterman, S., Van Der Wilt, G. J., & Spauwen, P. H. (2008). Surgeons underestimate their patients' desire for preoperative information. World J Surg, 32(6), 964-970. doi:10.1007/s00268-008-9581-1

Kew, F. M., Galaal, K., & Manderville, H. (2009). Patients' views of follow-up after treatment for gynaecological cancer. J Obstet Gynaecol, 29(2), 135-142. doi:10.1080/01443610802646801

King, J., Wynne, C. H., Assersohn, L., & Jones, A. (2011). Hormone replacement therapy and women with premature menopause--a cancer survivorship issue. Eur J Cancer, 47(11), 1623-1632. doi:10.1016/j.ejca.2011.04.007

Kjaer, S. K., Mellemkjaer, L., Brinton, L. A., Johansen, C., Gridley, G., & Olsen, J. H. (2004). Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65 000 sterilized women. Int J Epidemiol, 33(3), 596-602. doi:10.1093/ije/dyh046

Kohler, C., Klemm, P., Schau, A., Possover, M., Krause, N., Tozzi, R., & Schneider, A. (2004). Introduction of transperitoneal lymphadenectomy in a gynecologic oncology center: analysis of 650 laparoscopic pelvic and/or paraaortic transperitoneal lymphadenectomies. Gynecol Oncol, 95(1), 52-61. doi:10.1016/j.ygyno.2004.07.025

Kondrup, J., Rasmussen, H. H., Hamberg, O., & Stanga, Z. (2003). Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr, 22(3), 321-336. 

Kotsopoulos, J., Gronwald, J., Karlan, B. Y., Huzarski, T., Tung, N., Moller, P., . . . Narod, S. A. (2018). Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncol, 4(8), 1059-1065. doi:10.1001/jamaoncol.2018.0211

Kotsopoulos, J., Huzarski, T., Gronwald, J., Moller, P., Lynch, H. T., Neuhausen, S. L., . . . Narod, S. A. (2016). Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat, 155(2), 365-373. doi:10.1007/s10549-016-3685-3

Koyama, H., Wada, T., Nishizawa, Y., Iwanaga, T., & Aoki, Y. (1977). Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer, 39(4), 1403-1409. 

Krebs, H. B., & Goplerud, D. R. (1983). Surgical management of bowel obstruction in advanced ovarian carcinoma. Obstet Gynecol, 61(3), 327-330. 

Krell, D., Said Battistino, F., Benafif, S., Ganegoda, L., Hall, M., & Rustin, G. J. S. (2017). Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer. Int J Gynecol Cancer, 27(6), 1118-1122. doi:10.1097/igc.0000000000000956

Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M., Roos-Blom, M. J., . . . Olsson, H. (2017). Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA, 317(23), 2402-2416. doi:10.1001/jama.2017.7112

Kucukmetin, A., Naik, R., Galaal, K., Bryant, A., & Dickinson, H. O. (2010). Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Cochrane Database Syst Rev(7), CD007792. doi:10.1002/14651858.CD007792.pub2

Kumar Dhingra, V., Kand, P., & Basu, S. (2012). Impact of FDG-PET and -PET/CT imaging in the clinical decision-making of ovarian carcinoma: an evidence-based approach. Womens Health (Lond), 8(2), 191-203. doi:10.2217/whe.11.91

Kumpulainen, S., Grenman, S., Kyyronen, P., Pukkala, E., & Sankila, R. (2002). Evidence of benefit from centralised treatment of ovarian cancer: a nationwide population-based survival analysis in Finland. Int J Cancer, 102(5), 541-544. doi:10.1002/ijc.10754

Kurman, R. J., & Shih Ie, M. (2016). The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol, 186(4), 733-747. doi:10.1016/j.ajpath.2015.11.011

Kwan, M. L., Cohn, J. C., Armer, J. M., Stewart, B. R., & Cormier, J. N. (2011). Exercise in patients with lymphedema: a systematic review of the contemporary literature. J Cancer Surviv, 5(4), 320-336. doi:10.1007/s11764-011-0203-9

Kyriazi, S., Collins, D. J., Messiou, C., Pennert, K., Davidson, R. L., Giles, S. L., . . . Desouza, N. M. (2011). Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging--value of histogram analysis of apparent diffusion coefficients. Radiology, 261(1), 182-192. doi:10.1148/radiol.11110577

Labidi-Galy, S. I., Papp, E., Hallberg, D., Niknafs, N., Adleff, V., Noe, M., . . . Velculescu, V. E. (2017). High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun, 8(1), 1093. doi:10.1038/s41467-017-00962-1

Lamb, B. W., Brown, K. F., Nagpal, K., Vincent, C., Green, J. S., & Sevdalis, N. (2011). Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Ann Surg Oncol, 18(8), 2116-2125. doi:10.1245/s10434-011-1675-6

Lamb, B. W., Green, J. S., Benn, J., Brown, K. F., Vincent, C. A., & Sevdalis, N. (2013). Improving decision making in multidisciplinary tumor boards: prospective longitudinal evaluation of a multicomponent intervention for 1,421 patients. J Am Coll Surg, 217(3), 412-420. doi:10.1016/j.jamcollsurg.2013.04.035

Lanceley, A., Berzuini, C., Burnell, M., Gessler, S., Morris, S., Ryan, A., . . . Jacobs, I. (2017). Ovarian Cancer Follow-up: A Preliminary Comparison of 2 Approaches. Int J Gynecol Cancer, 27(1), 59-68. doi:10.1097/igc.0000000000000877

Langdon, S. P., Gourley, C., Gabra, H., & Stanley, B. (2017). Endocrine therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther, 17(2), 109-117. doi:10.1080/14737140.2017.1272414

Lawrie, T. A., Winter-Roach, B. A., Heus, P., & Kitchener, H. C. (2015). Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev(12), Cd004706. doi:10.1002/14651858.CD004706.pub5

Leandersson, P., Granasen, G., & Borgfeldt, C. (2017). Ovarian Cancer Surgery - A Population-based Registry Study. Anticancer Res, 37(4), 1837-1845. doi:10.21873/anticanres.11519

Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., . . . Matulonis, U. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med, 366(15), 1382-1392. doi:10.1056/NEJMoa1105535

Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., . . . Matulonis, U. (2014). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol, 15(8), 852-861. doi:10.1016/s1470-2045(14)70228-1

Ledermann, J. A., Embleton, A. C., Perren, T., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., . . . Collaborators, I. (2017). Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer. 35(15_suppl), 5506-5506. doi:10.1200/JCO.2017.35.15_suppl.5506

Ledermann, J. A., Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., . . . Parmar, M. K. B. (2016). Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 387(10023), 1066-1074. doi:10.1016/s0140-6736(15)01167-8

Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013). Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 24 Suppl 6, vi24-32. doi:10.1093/annonc/mdt333

Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2018). Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 29(Supplement_4), iv259. doi:10.1093/annonc/mdy157

Leiserowitz, G. S. (2006). Managing ovarian masses during pregnancy. Obstet Gynecol Surv, 61(7), 463-470. doi:10.1097/01.ogx.0000224614.51356.b7

Lenhard, M. S., Mitterer, S., Kumper, C., Stieber, P., Mayr, D., Ditsch, N., . . . Burges, A. (2009). Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol, 145(2), 189-194. doi:10.1016/j.ejogrb.2009.04.031

Leon-Ferre, R. A., Majithia, N., & Loprinzi, C. L. (2017). Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev, 52, 82-90. doi:10.1016/j.ctrv.2016.11.012

Li, D., Ding, C. Y., & Qiu, L. H. (2015). Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol, 139(2), 355-362. doi:10.1016/j.ygyno.2015.07.109

Liavaag, A. H., Dorum, A., Bjoro, T., Oksefjell, H., Fossa, S. D., Trope, C., & Dahl, A. A. (2008). A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol Oncol, 108(2), 348-354. doi:10.1016/j.ygyno.2007.10.009

Lim, M. C., Chang, S.-J., Yoo, H. J., Nam, B.-H., Bristow, R., & Park, S.-Y. (2017). Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. 35(15_suppl), 5520-5520. doi:10.1200/JCO.2017.35.15_suppl.5520

Lindemann, K., Gibbs, E., Avall-Lundqvist, E., dePont Christensen, R., Woie, K., Kalling, M., . . . Kristensen, G. (2017). Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer, 116(4), 455-463. doi:10.1038/bjc.2016.435

Lindmark G. Läkemedelsbehandling under graviditet. I Obstetrisk öppenvård. Red. Marsal, Grennert Liber 2004; 91-101. 

Link, K. H., Roitman, M., Holtappels, M., Runnebaum, I., Urbanzyk, H., Leder, G., & Staib, L. (2003). Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am, 12(3), 865-872, xvi-xvii. 

Lithner, M., & Zilling, T. (1998). Does preoperative information increase the wellbeing of the patient after surgery? (in Swedish). . In Vård i Norden (pp. 31-33, 39).

Liu, J. F., Barry, W. T., Birrer, M., Lee, J. M., Buckanovich, R. J., Fleming, G. F., . . . Matulonis, U. A. (2014). Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol, 15(11), 1207-1214. doi:10.1016/s1470-2045(14)70391-2

Ljungqvist, O., Scott, M., & Fearon, K. C. (2017). Enhanced Recovery After Surgery: A Review. JAMA Surg, 152(3), 292-298. doi:10.1001/jamasurg.2016.4952

Loveday, C., Turnbull, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J. R., . . . Rahman, N. (2011). Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet, 43(9), 879-882. doi:10.1038/ng.893

Loveday, C., Turnbull, C., Ruark, E., Xicola, R. M., Ramsay, E., Hughes, D., . . . Rahman, N. (2012). Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet, 44(5), 475-476; author reply 476. doi:10.1038/ng.2224

Luan, N. N., Wu, Q. J., Gong, T. T., Vogtmann, E., Wang, Y. L., & Lin, B. (2013). Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies. Am J Clin Nutr, 98(4), 1020-1031. doi:10.3945/ajcn.113.062794

Lundström, S. Tema, Palliativ medicin. Farmakologisk smärtlindring har central roll i palliativ vård. Lakartidningen, 113. 

Mabuchi, S., Sugiyama, T., & Kimura, T. (2016). Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol, 27(3), e31. doi:10.3802/jgo.2016.27.e31

Macdonald, G., Kondor, N., Yousefi, V., Green, A., Wong, F., & Aquino-Parsons, C. (2004). Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol, 73(3), 367-371. doi:10.1016/j.radonc.2004.09.002

Mahdi, H., Wiechert, A., Lockhart, D., & Rose, P. G. (2015). Impact of Age on 30-Day Mortality and Morbidity in Patients Undergoing Surgery for Ovarian Cancer. Int J Gynecol Cancer, 25(7), 1216-1223. doi:10.1097/igc.0000000000000486

Mahner, S., Eulenburg, C., Staehle, A., Wegscheider, K., Reuss, A., Pujade-Lauraine, E., . . . du Bois, A. (2013). Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer, 49(1), 142-149. doi:10.1016/j.ejca.2012.07.023

Mahner, S., Trillsch, F., Chi, D., Harter, P., Pfisterer, J., Hilpert, F., . . . du Bois, A. (2016). Neoadjuvant chemotherapy in ovarian cancer revisited. Ann Oncol, 27 Suppl 1, i30-i32. doi:10.1093/annonc/mdw092

Malekzadeh, F., et al. (2005). Naturläkemedel och hormonpreparat - potentiell risk för bröstcancerpatienter. , 102.

Manning-Geist, B. L., Alimena, S., Del Carmen, M. G., Goodman, A., Clark, R. M., Growdon, W. B., . . . Worley, M. J., Jr. (2019). Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter? Gynecol Oncol, 153(1), 63-67. doi:10.1016/j.ygyno.2019.01.001

Marinaccio M, Mele E, De Marino E, Catacchio R, Pellegrino C, Sozzi F, S. Schonauer S. Intraperitoneal mitoxantrone in the treatment of recurrent ascites from progressive epithelial ovarian cancer.J Clin Oncol 28:15s, 2010 (suppl; abstr 5051). 

Marret, H., Lhomme, C., Lecuru, F., Canis, M., Leveque, J., Golfier, F., & Morice, P. (2010). Guidelines for the management of ovarian cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol, 149(1), 18-21. doi:10.1016/j.ejogrb.2009.12.001

Mascarenhas, C., Lambe, M., Bellocco, R., Bergfeldt, K., Riman, T., Persson, I., & Weiderpass, E. (2006). Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer, 119(12), 2907-2915. doi:10.1002/ijc.22218

Matulonis, U. A., Kornblith, A., Lee, H., Bryan, J., Gibson, C., Wells, C., . . . Penson, R. (2008). Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer, 18(6), 1183-1193. doi:10.1111/j.1525-1438.2007.01167.x

Matulonis, U. A., Shapira-Frommer, R., Santin, A., Lisyanskaya, A. S., Pignata, S., Vergote, I., . . . Ledermann, J. A. (2018). Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. 36(15_suppl), 5511-5511. doi:10.1200/JCO.2018.36.15_suppl.5511

McAlpine, J. N., Porter, H., Kobel, M., Nelson, B. H., Prentice, L. M., Kalloger, S. E., . . . Gilks, C. B. (2012). BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol, 25(5), 740-750. doi:10.1038/modpathol.2011.211

McCluggage, W. G., Hirschowitz, L., Gilks, C. B., Wilkinson, N., & Singh, N. (2017). The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians. Int J Gynecol Pathol, 36(3), 230-239. doi:10.1097/pgp.0000000000000336

McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., . . . Davidson, M. (1996). Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol, 23(5 Suppl 12), 40-47. 

McLaughlin, J. R., Risch, H. A., Lubinski, J., Moller, P., Ghadirian, P., Lynch, H., . . . Hereditary Ovarian Cancer Clinical Study, G. (2007). Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol, 8(1), 26-34. doi:10.1016/S1470-2045(06)70983-4

McLaughlin, S. A., Wright, M. J., Morris, K. T., Sampson, M. R., Brockway, J. P., Hurley, K. E., . . . Van Zee, K. J. (2008). Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. J Clin Oncol, 26(32), 5220-5226. doi:10.1200/JCO.2008.16.3766

Medeiros, L. R., Freitas, L. B., Rosa, D. D., Silva, F. R., Silva, L. S., Birtencourt, L. T., . . . Rosa, M. I. (2011). Accuracy of magnetic resonance imaging in ovarian tumor: a systematic quantitative review. Am J Obstet Gynecol, 204(1), 67 e61-10. doi:10.1016/j.ajog.2010.08.031

Meyer, L. A., Lasala, J., Iniesta, M. D., Nick, A. M., Munsell, M. F., Shi, Q., . . . Ramirez, P. T. (2018). Effect of an Enhanced Recovery After Surgery Program on Opioid Use and Patient-Reported Outcomes. Obstet Gynecol, 132(2), 281-290. doi:10.1097/aog.0000000000002735

Michielsen, K., Dresen, R., Vanslembrouck, R., De Keyzer, F., Amant, F., Mussen, E., . . . Vandecaveye, V. (2017). Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. Eur J Cancer, 83, 88-98. doi:10.1016/j.ejca.2017.06.010

Michielsen, K., Vergote, I., Op de Beeck, K., Amant, F., Leunen, K., Moerman, P., . . . Vandecaveye, V. (2014). Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol, 24(4), 889-901. doi:10.1007/s00330-013-3083-8

Mijwel, S., Backman, M., Bolam, K. A., Jervaeus, A., Sundberg, C. J., Margolin, S., . . . Wengstrom, Y. (2018). Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial. Breast Cancer Res Treat, 168(1), 79-93. doi:10.1007/s10549-017-4571-3

Mijwel, S., Backman, M., Bolam, K. A., Olofsson, E., Norrbom, J., Bergh, J., . . . Rundqvist, H. (2018). Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial. Breast Cancer Res Treat, 169(1), 93-103. doi:10.1007/s10549-018-4663-8

Minig, L., Heitz, F., Cibula, D., Bakkum-Gamez, J. N., Germanova, A., Dowdy, S. C., . . . Fotopoulou, C. (2017). Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study. Ann Surg Oncol, 24(9), 2720-2726. doi:10.1245/s10434-017-5919-y

Mir, O., Berveiller, P., Goffinet, F., Treluyer, J. M., Serreau, R., Goldwasser, F., & Rouzier, R. (2010). Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol, 21(2), 425-426. doi:10.1093/annonc/mdp517

Mirza, M. R., Avall Lundqvist, E., Birrer, M. J., dePont Christensen, R., Nyvang, G. B., Malander, S., . . . Maenpaa, J. U. (2019). Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. doi:10.1016/s1470-2045(19)30515-7

Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., . . . Matulonis, U. A. (2016). Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med, 375(22), 2154-2164. doi:10.1056/NEJMoa1611310

Mobus, V., Wandt, H., Frickhofen, N., Bengala, C., Champion, K., Kimmig, R., . . . Ebmt. (2007). Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol, 25(27), 4187-4193. doi:10.1200/JCO.2006.09.7527

Mokri, B., Mariani, A., Heit, J. A., Weaver, A. L., McGree, M. E., Martin, J. R., . . . Bakkum-Gamez, J. N. (2013). Incidence and predictors of venous thromboembolism after debulking surgery for epithelial ovarian cancer. Int J Gynecol Cancer, 23(9), 1684-1691. doi:10.1097/IGC.0b013e3182a80aa7

Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., . . . Poveda, A. M. (2010). Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol, 28(19), 3107-3114. doi:10.1200/JCO.2009.25.4037

Monk, B. J., Huang, H. Q., Burger, R. A., Mannel, R. S., Homesley, H. D., Fowler, J., . . . Wenzel, L. (2013). Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol, 128(3), 573-578. doi:10.1016/j.ygyno.2012.11.038

Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M., . . . DiSilvestro, P. (2018). Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med, 379(26), 2495-2505. doi:10.1056/NEJMoa1810858

Moore, K. N., Mirza, M. R., & Matulonis, U. A. (2018). The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol, 149(1), 214-220. doi:10.1016/j.ygyno.2018.01.011

Moore, R. G., Brown, A. K., Miller, M. C., Skates, S., Allard, W. J., Verch, T., . . . Bast, R. C., Jr. (2008). The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol, 108(2), 402-408. doi:10.1016/j.ygyno.2007.10.017

Moore, R. G., Jabre-Raughley, M., Brown, A. K., Robison, K. M., Miller, M. C., Allard, W. J., . . . Skates, S. J. (2010). Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol, 203(3), 228 e221-226. doi:10.1016/j.ajog.2010.03.043

Moore, R. G., McMeekin, D. S., Brown, A. K., DiSilvestro, P., Miller, M. C., Allard, W. J., . . . Skates, S. J. (2009). A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol, 112(1), 40-46. doi:10.1016/j.ygyno.2008.08.031

Morch, L. S., Lokkegaard, E., Andreasen, A. H., Kruger-Kjaer, S., & Lidegaard, O. (2009). Hormone therapy and ovarian cancer. JAMA, 302(3), 298-305. doi:10.1001/jama.2009.1052

Morgan, R. J., Jr., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L. M., . . . Hughes, M. (2016). Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 14(9), 1134-1163. 

Morice, P., Denschlag, D., Rodolakis, A., Reed, N., Schneider, A., Kesic, V., . . . Fertility Task Force of the European Society of Gynecologic, O. (2011). Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. Int J Gynecol Cancer, 21(5), 951-963. doi:10.1097/IGC.0b013e31821bec6b

Morton, R., Anderson, L., Carter, J., Pather, S., & Saidi, S. A. (2017). Intraoperative Frozen Section of Ovarian Tumors: A 6-Year Review of Performance and Potential Pitfalls in an Australian Tertiary Referral Center. Int J Gynecol Cancer, 27(1), 17-21. doi:10.1097/igc.0000000000000851

Mourton, S. M., Temple, L. K., Abu-Rustum, N. R., Gemignani, M. L., Sonoda, Y., Bochner, B. H., . . . Chi, D. S. (2005). Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol, 99(3), 608-614. doi:10.1016/j.ygyno.2005.07.112

Moyle, P., Addley, H. C., & Sala, E. (2010). Radiological staging of ovarian carcinoma. Semin Ultrasound CT MR, 31(5), 388-398. doi:10.1053/j.sult.2010.07.003

Muka, T., Oliver-Williams, C., Kunutsor, S., Laven, J. S., Fauser, B. C., Chowdhury, R., . . . Franco, O. H. (2016). Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis. JAMA Cardiol, 1(7), 767-776. doi:10.1001/jamacardio.2016.2415

Munkarah, A. R., & Coleman, R. L. (2004). Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol, 95(2), 273-280. doi:10.1016/j.ygyno.2004.09.018

Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S. D., . . . Secord, A. A. (2007). Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol, 25(19), 2811-2818. doi:10.1200/JCO.2006.09.6735

Mutch, D. G., & Prat, J. (2014). 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol, 133(3), 401-404. doi:10.1016/j.ygyno.2014.04.013

Nakamura, K., Banno, K., Yanokura, M., Iida, M., Adachi, M., Masuda, K., . . . Aoki, D. (2014). Features of ovarian cancer in Lynch syndrome (Review). Mol Clin Oncol, 2(6), 909-916. doi:10.3892/mco.2014.397

Nath, B., Li, Y., Carroll, J. E., Szabo, G., Tseng, J. F., & Shah, S. A. (2010). Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg, 14(11), 1732-1741. doi:10.1007/s11605-010-1350-4

Nathorst-Boos, J., & von Schoultz, B. (1992). Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol Obstet Invest, 34(2), 97-101. 

Nelson, G., Altman, A. D., Nick, A., Meyer, L. A., Ramirez, P. T., Achtari, C., . . . Dowdy, S. C. (2016a). Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS(R)) Society recommendations--Part II. Gynecol Oncol, 140(2), 323-332. doi:10.1016/j.ygyno.2015.12.019

Nelson, G., Altman, A. D., Nick, A., Meyer, L. A., Ramirez, P. T., Achtari, C., . . . Dowdy, S. C. (2016b). Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS(R)) Society recommendations--Part I. Gynecol Oncol, 140(2), 313-322. doi:10.1016/j.ygyno.2015.11.015

Nelson, G., Kalogera, E., & Dowdy, S. C. (2014). Enhanced recovery pathways in gynecologic oncology. Gynecol Oncol, 135(3), 586-594. doi:10.1016/j.ygyno.2014.10.006

Nezhat, F., Datta, M. S., Hanson, V., Pejovic, T., Nezhat, C., & Nezhat, C. (2008). The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril, 90(5), 1559-1570. doi:10.1016/j.fertnstert.2008.08.007

Nezhat, F. R., Ezzati, M., Chuang, L., Shamshirsaz, A. A., Rahaman, J., & Gretz, H. (2009). Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome. Am J Obstet Gynecol, 200(1), 83 e81-86. doi:10.1016/j.ajog.2008.08.013

Ngu, S. F., Cheung, V. Y., & Pun, T. C. (2011). Left upper quadrant approach in gynecologic laparoscopic surgery. Acta Obstet Gynecol Scand, 90(12), 1406-1409. doi:10.1111/j.1600-0412.2011.01257.x

Ngu, S. F., & Ngan, H. Y. (2016). Chemotherapy in pregnancy. Best Pract Res Clin Obstet Gynaecol, 33, 86-101. doi:10.1016/j.bpobgyn.2015.10.007

NICE clinical guideline. Ovarian cancer: the recognition and initial management of ovarian cancer. Full guideline april 2011. Published by the National Collaborating Centre for Cancer at Velindre NHS Trust, Cardiff, Wales. ISBN 978-0-9558265-5-9. 

NICE clinical guidelines nr 122; ovarian cancer: the recognition and initial management of ovarian cancer 2011. 

NLT-gruppens yttrande till landstingen gällande bevacizumab (Avastin®).

Hallberg A. 2014-06-16. Sveriges kommuner och landsting 

Nolen, B., Velikokhatnaya, L., Marrangoni, A., De Geest, K., Lomakin, A., Bast, R. C., Jr., & Lokshin, A. (2010). Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol, 117(3), 440-445. doi:10.1016/j.ygyno.2010.02.005

Norquist, B. M., Harrell, M. I., Brady, M. F., Walsh, T., Lee, M. K., Gulsuner, S., . . . Birrer, M. J. (2016). Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol, 2(4), 482-490. doi:10.1001/jamaoncol.2015.5495

Norton, L., & Simon, R. (1986). The Norton-Simon hypothesis revisited. Cancer Treat Rep, 70(1), 163-169. 

Oaknin, A., Balmanoukian, A. S., Liu, B., O'Hear, C., Braiteh, F., Infante, J. R., . . . Wang, Y. (2016). Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC). Annals of Oncology, 27(suppl_6). doi:10.1093/annonc/mdw374.18 %J Annals of Oncology

Obermair, A., Hagenauer, S., Tamandl, D., Clayton, R. D., Nicklin, J. L., Perrin, L. C., . . . Crandon, A. J. (2001). Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol, 83(1), 115-120. doi:10.1006/gyno.2001.6353

Oktay, K., Turkcuoglu, I., & Rodriguez-Wallberg, K. A. (2010). GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online, 20(6), 783-788. doi:10.1016/j.rbmo.2010.03.004

Olsen, C. M., Bain, C. J., Jordan, S. J., Nagle, C. M., Green, A. C., Whiteman, D. C., . . . Australian Ovarian Cancer Study, G. (2007). Recreational physical activity and epithelial ovarian cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev, 16(11), 2321-2330. doi:10.1158/1055-9965.EPI-07-0566

Olsen, C. M., Nagle, C. M., Whiteman, D. C., Ness, R., Pearce, C. L., Pike, M. C., . . . Ovarian Cancer Association, C. (2013). Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer, 20(2), 251-262. doi:10.1530/ERC-12-0395

Onda, T., Satoh, T., Saito, T., Kasamatsu, T., Nakanishi, T., Nakamura, K., . . . Yoshikawa, H. (2016). Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer, 64, 22-31. doi:10.1016/j.ejca.2016.05.017

Oppedal, K., Moller, A. M., Pedersen, B., & Tonnesen, H. (2012). Preoperative alcohol cessation prior to elective surgery. Cochrane Database Syst Rev(7), Cd008343. doi:10.1002/14651858.CD008343.pub2

Oseledchyk, A., Leitao, M. M., Jr., Konner, J., O'Cearbhaill, R. E., Zamarin, D., Sonoda, Y., . . . Zivanovic, O. (2017). Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013. Ann Oncol, 28(12), 2985-2993. doi:10.1093/annonc/mdx525

Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., . . . Perren, T. J. (2015). Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol, 16(8), 928-936. doi:10.1016/s1470-2045(15)00086-8

Ozga, M., Aghajanian, C., Myers-Virtue, S., McDonnell, G., Jhanwar, S., Hichenberg, S., & Sulimanoff, I. (2015). A systematic review of ovarian cancer and fear of recurrence. Palliat Support Care, 13(6), 1771-1780. doi:10.1017/s1478951515000127

Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., . . . Gynecologic Oncology, G. (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol, 21(17), 3194-3200. doi:10.1200/JCO.2003.02.153

Pal, T., Permuth-Wey, J., Kumar, A., & Sellers, T. A. (2008). Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res, 14(21), 6847-6854. doi:10.1158/1078-0432.CCR-08-1387

Paluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M. J., Gilbert, F., & Senkus, E. (2016). Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol, 27(suppl 5), v103-v110. doi:10.1093/annonc/mdw327

Park, H. J., Kim, D. W., Yim, G. W., Nam, E. J., Kim, S., & Kim, Y. T. (2013). Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis. Am J Obstet Gynecol, 209(1), 58.e51-58. doi:10.1016/j.ajog.2013.04.013

Park, J. Y., Kim, D. Y., Suh, D. S., Kim, J. H., Kim, Y. M., Kim, Y. T., & Nam, J. H. (2008). Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol, 110(3), 345-353. doi:10.1016/j.ygyno.2008.04.040

Parker, P. A., Kudelka, A., Basen-Engquist, K., Kavanagh, J., de Moor, J., & Cohen, L. (2006). The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecol Oncol, 100(3), 495-500. doi:10.1016/j.ygyno.2005.08.057

Parmar, M. K., Ledermann, J. A., Colombo, N., du Bois, A., Delaloye, J. F., Kristensen, G. B., . . . Collaborators, A. G. O. (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 361(9375), 2099-2106. 

Pavlidis, N. A. (2002). Coexistence of pregnancy and malignancy. Oncologist, 7(4), 279-287. 

Pearce, C. L., Chung, K., Pike, M. C., & Wu, A. H. (2009). Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer, 115(3), 531-539. doi:10.1002/cncr.23956

Pearce, C. L., Templeman, C., Rossing, M. A., Lee, A., Near, A. M., Webb, P. M., . . . Berchuck, A. (2012). Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol, 13(4), 385-394. doi:10.1016/s1470-2045(11)70404-1

Peccatori, F. A., Azim, H. A., Jr., Orecchia, R., Hoekstra, H. J., Pavlidis, N., Kesic, V., . . . Group, E. G. W. (2013). Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 24 Suppl 6, vi160-170. doi:10.1093/annonc/mdt199

Peiretti, M., Bristow, R. E., Zapardiel, I., Gerardi, M., Zanagnolo, V., Biffi, R., . . . Maggioni, A. (2012). Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol, 126(2), 220-223. doi:10.1016/j.ygyno.2012.04.030

Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., . . . Swisher, E. M. (2014). Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res, 20(3), 764-775. doi:10.1158/1078-0432.Ccr-13-2287

Pentheroudakis, G., Orecchia, R., Hoekstra, H. J., Pavlidis, N., & Group, E. G. W. (2010). Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21 Suppl 5, v266-273. doi:10.1093/annonc/mdq198

Pereira, P. N., Sarian, L. O., Yoshida, A., Araujo, K. G., Barros, R. H. O., Baiao, A. C., . . . Derchain, S. (2018). Accuracy of the ADNEX MR scoring system based on a simplified MRI protocol for the assessment of adnexal masses. Diagn Interv Radiol, 24(2), 63-71. doi:10.5152/dir.2018.17378

Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., . . . Investigators, I. (2011). A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med, 365(26), 2484-2496. doi:10.1056/NEJMoa1103799

Peterson, C. (2005). Naturläkemedel - egenvård på egen risk! Fara för okända biverkningar och interaktioner med "vanliga" läkemedel. . Lakartidningen, 102.

Petrillo, M., Vizzielli, G., Fanfani, F., Gallotta, V., Cosentino, F., Chiantera, V., . . . Fagotti, A. (2015). Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept. Gynecol Oncol, 139(1), 5-9. doi:10.1016/j.ygyno.2015.07.095

Pfisterer, J., Dean, A. P., Baumann, K., & Rau, J. P. (2018). Carboplatin/pegylated liposomal Doxorubicin/Bevacizumab (CD-BEV) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in patients with recurrent ovarian cancer (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285). . Paper presented at the Annals of Oncology. 

Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., . . . Eortc, G. C. G. (2006). Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol, 24(29), 4699-4707. doi:10.1200/JCO.2006.06.0913

Pfisterer, J., Weber, B., Reuss, A., Kimmig, R., du Bois, A., Wagner, U., . . . Gineco. (2006). Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst, 98(15), 1036-1045. doi:10.1093/jnci/djj296

Piccart, M. J., Bertelsen, K., James, K., Cassidy, J., Mangioni, C., Simonsen, E., . . . Pecorelli, S. (2000). Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst, 92(9), 699-708. 

Pignata, S., Lorusso, D., Joly, F., Gallo, C., Colombo, N., Sessa, C., . . . groups, H. (2018). Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. 36(15_suppl), 5506-5506. doi:10.1200/JCO.2018.36.15_suppl.5506

Pignata, S., S, C. C., Du Bois, A., Harter, P., & Heitz, F. (2017). Treatment of recurrent ovarian cancer. Ann Oncol, 28(suppl_8), viii51-viii56. doi:10.1093/annonc/mdx441

Pignata, S., Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., . . . Perrone, F. (2011). Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol, 29(27), 3628-3635. doi:10.1200/JCO.2010.33.8566

Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., . . . Gynecologic Cancer InterGroup, I. (2014). Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol, 15(4), 396-405. doi:10.1016/S1470-2045(14)70049-X

Pilger, A., Richter, R., Fotopoulou, C., Beteta, C., Klapp, C., & Sehouli, J. (2012). Quality of life and sexuality of patients after treatment for gynaecological malignancies: results of a prospective study in 55 patients. Anticancer Res, 32(11), 5045-5049. 

Pinsky, P. F., Yu, K., Kramer, B. S., Black, A., Buys, S. S., Partridge, E., . . . Prorok, P. C. (2016). Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol Oncol, 143(2), 270-275. doi:10.1016/j.ygyno.2016.08.334

Pinsky, P. F., Zhu, C., Skates, S. J., Black, A., Partridge, E., Buys, S. S., & Berg, C. D. (2013). Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. Int J Cancer, 132(9), 2127-2133. doi:10.1002/ijc.27909

Piver, M. S., Lele, S. B., Marchetti, D. L., Baker, T. R., Tsukada, Y., & Emrich, L. J. (1988). The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol, 6(6), 983-989. doi:10.1200/jco.1988.6.6.983

Pommier, Y., O'Connor, M. J., & de Bono, J. (2016). Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med, 8(362), 362ps317. doi:10.1126/scitranslmed.aaf9246

Pothuri, B., Montemarano, M., Gerardi, M., Shike, M., Ben-Porat, L., Sabbatini, P., & Barakat, R. R. (2005). Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol, 96(2), 330-334. doi:10.1016/j.ygyno.2004.09.058

Poveda, A. M., Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I., . . . Pujade-Lauraine, E. (2015). Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. J Clin Oncol, 33(32), 3836-3838. doi:10.1200/jco.2015.63.1408

Prader, S., Harter, P., Grimm, C., Traut, A., Waltering, K. U., Alesina, P. F., . . . du Bois, A. (2016). Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer. Gynecol Oncol, 141(2), 271-275. doi:10.1016/j.ygyno.2016.03.012

Prat, J. (2014). Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet, 124(1), 1-5. doi:10.1016/j.ijgo.2013.10.001

Prat, J. (2015). Ovarian, fallopian tube and peritoneal cancer staging: Rationale and explanation of new FIGO staging 2013. Best Pract Res Clin Obstet Gynaecol, 29(6), 858-869. doi:10.1016/j.bpobgyn.2015.03.006

Prat, J., D'Angelo, E., & Espinosa, I. (2018). Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol, 80, 11-27. doi:10.1016/j.humpath.2018.06.018

Prat, J., & De Nictolis, M. (2002). Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol, 26(9), 1111-1128. 

Preliminära SFOG-råd för menopausal hormonbehandling 2019. Retrieved from https://www.sfog.se/media/336474/mht-sfog-raad-preliminar-hemsida.pdf

Prentice, R. L., Thomson, C. A., Caan, B., Hubbell, F. A., Anderson, G. L., Beresford, S. A., . . . Chlebowski, R. T. (2007). Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst, 99(20), 1534-1543. doi:10.1093/jnci/djm159

Prochazka, M., Granath, F., Ekbom, A., Shields, P. G., & Hall, P. (2002). Lung cancer risks in women with previous breast cancer. Eur J Cancer, 38(11), 1520-1525. 

Provencher, D. M., Gallagher, C. J., Parulekar, W. R., Ledermann, J. A., Armstrong, D. K., Brundage, M., . . . MacKay, H. J. (2018). OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Ann Oncol, 29(2), 431-438. doi:10.1093/annonc/mdx754

Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., . . . Ray-Coquard, I. (2014). Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol, 32(13), 1302-1308. doi:10.1200/JCO.2013.51.4489

Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., . . . Pautier, P. (2017). Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 18(9), 1274-1284. doi:10.1016/s1470-2045(17)30469-2

Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., . . . du Bois, A. (2010). Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol, 28(20), 3323-3329. doi:10.1200/JCO.2009.25.7519

Purdie, D. M., Bain, C. J., Siskind, V., Webb, P. M., & Green, A. C. (2003). Ovulation and risk of epithelial ovarian cancer. Int J Cancer, 104(2), 228-232. doi:10.1002/ijc.10927

Querleu, D., Planchamp, F., Chiva, L., Fotopoulou, C., Barton, D., Cibula, D., . . . du Bois, A. (2016). European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery. Int J Gynecol Cancer, 26(7), 1354-1363. doi:10.1097/igc.0000000000000767

Raffles, A., Williams, J., Costeloe, K., & Clark, P. (1989). Transplacental effects of maternal cancer chemotherapy. Case report. Br J Obstet Gynaecol, 96(9), 1099-1100. 

Rafnar, T., Gudbjartsson, D. F., Sulem, P., Jonasdottir, A., Sigurdsson, A., Jonasdottir, A., . . . Stefansson, K. (2011). Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet, 43(11), 1104-1107. doi:10.1038/ng.955

Ramus, S. J., Song, H., Dicks, E., Tyrer, J. P., Rosenthal, A. N., Intermaggio, M. P., . . . Gayther, S. A. (2015). Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst, 107(11). doi:10.1093/jnci/djv214

Ratnavelu, N. D., Brown, A. P., Mallett, S., Scholten, R. J., Patel, A., Founta, C., . . . Naik, R. (2016). Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses. Cochrane Database Syst Rev, 3, Cd010360. doi:10.1002/14651858.CD010360.pub2

Ratner, E. S., Foran, K. A., Schwartz, P. E., & Minkin, M. J. (2010). Sexuality and intimacy after gynecological cancer. Maturitas, 66(1), 23-26. doi:10.1016/j.maturitas.2010.01.015

Rauh-Hain, J. A., Melamed, A., Wright, A., Gockley, A., Clemmer, J. T., Schorge, J. O., . . . Keating, N. L. (2017). Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol, 3(1), 76-82. doi:10.1001/jamaoncol.2016.4411

Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alía, E. M., Reinthaller, A., Nagao, S., Lefeuvre-Plesse, C., Canzler, U., Scambia, G., Lortholary, A., … PAOLA-1 Investigators (2019). Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. The New England journal of medicine381(25), 2416–2428. https://doi.org/10.1056/NEJMoa1911361

Reade, C. J., McVey, R. M., Tone, A. A., Finlayson, S. J., McAlpine, J. N., Fung-Kee-Fung, M., & Ferguson, S. E. (2014). The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. J Obstet Gynaecol Can, 36(2), 133-140. doi:10.1016/s1701-2163(15)30659-9

Rebbeck, T. R., Friebel, T., Wagner, T., Lynch, H. T., Garber, J. E., Daly, M. B., . . . Weber, B. L. (2005). Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol, 23(31), 7804-7810. doi:10.1200/jco.2004.00.8151

Reid, A., Ercolano, E., Schwartz, P., & McCorkle, R. (2011). The management of anxiety and knowledge of serum CA-125 after an ovarian cancer diagnosis. Clin J Oncol Nurs, 15(6), 625-632. doi:10.1188/11.Cjon.625-632

Reid, B. M., Permuth, J. B., & Sellers, T. A. (2017). Epidemiology of ovarian cancer: a review. Cancer Biol Med, 14(1), 9-32. doi:10.20892/j.issn.2095-3941.2016.0084

Ren, J., Peng, Z., & Yang, K. (2008). A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors. Gynecol Oncol, 110(2), 162-167. doi:10.1016/j.ygyno.2008.03.019

Ricci, F., Affatato, R., Carrassa, L., & Damia, G. (2018). Recent Insights into Mucinous Ovarian Carcinoma. Int J Mol Sci, 19(6). doi:10.3390/ijms19061569

Ring, A. E., Smith, I. E., Jones, A., Shannon, C., Galani, E., & Ellis, P. A. (2005). Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol, 23(18), 4192-4197. doi:10.1200/JCO.2005.03.038

Risum, S., Hogdall, C., Loft, A., Berthelsen, A. K., Hogdall, E., Nedergaard, L., . . . Engelholm, S. A. (2010). Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer? Gynecol Oncol, 116(3), 395-398. doi:10.1016/j.ygyno.2009.12.008

Rivera, C. M., Grossardt, B. R., Rhodes, D. J., & Rocca, W. A. (2009). Increased mortality for neurological and mental diseases following early bilateral oophorectomy. Neuroepidemiology, 33(1), 32-40. doi:10.1159/000211951

Rizzuto, I., Behrens, R. F., & Smith, L. A. (2013). Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev, 8, CD008215. doi:10.1002/14651858.CD008215.pub2

Rocca, W. A., Gazzuola-Rocca, L., Smith, C. Y., Grossardt, B. R., Faubion, S. S., Shuster, L. T., . . . Miller, V. M. (2016). Accelerated Accumulation of Multimorbidity After Bilateral Oophorectomy: A Population-Based Cohort Study. Mayo Clin Proc, 91(11), 1577-1589. doi:10.1016/j.mayocp.2016.08.002

Rodriguez-Wallberg, K., Turan, V., Munster, P., & Oktay, K. (2016). Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients? Ann Oncol, 27(2), 357. doi:10.1093/annonc/mdv554

Rodriguez-Wallberg, K. A., Tanbo, T., Tinkanen, H., Thurin-Kjellberg, A., Nedstrand, E., Kitlinski, M. L., . . . Andersen, C. Y. (2016). Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries - compilation of 20 years of multicenter experience. Acta Obstet Gynecol Scand, 95(9), 1015-1026. doi:10.1111/aogs.12934

Rosenberg, P., Andersson, H., Boman, K., Ridderheim, M., Sorbe, B., Puistola, U., & Paro, G. (2002). Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol, 41(5), 418-424. 

Rosenberg, S., Courtney, A., Nemcek, A. A., Jr., & Omary, R. A. (2004). Comparison of percutaneous management techniques for recurrent malignant ascites. J Vasc Interv Radiol, 15(10), 1129-1131. doi:10.1097/01.Rvi.0000136828.42612.B4

Rosenthal, A. N. (2012). Ovarian cancer screening in the high-risk population--the UK Familial Ovarian Cancer Screening Study (UKFOCSS). Int J Gynecol Cancer, 22 Suppl 1, S27-28. doi:10.1097/IGC.0b013e318251cc3f

Rosenthal, A. N., Fraser, L. S. M., Philpott, S., Manchanda, R., Burnell, M., Badman, P., . . . Jacobs, I. J. (2017). Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. J Clin Oncol, 35(13), 1411-1420. doi:10.1200/jco.2016.69.9330

Rossi, S., Baili, P., Capocaccia, R., Caldora, M., Carrani, E., Minicozzi, P., . . . De Angelis, R. (2015). The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods. Eur J Cancer, 51(15), 2104-2119. doi:10.1016/j.ejca.2015.08.001

Rota, M., Pasquali, E., Scotti, L., Pelucchi, C., Tramacere, I., Islami, F., . . . Bagnardi, V. (2012). Alcohol drinking and epithelial ovarian cancer risk. a systematic review and meta-analysis. Gynecol Oncol, 125(3), 758-763. doi:10.1016/j.ygyno.2012.03.031

Ruiz, M., Labauge, P., Louboutin, A., Limot, O., Fauconnier, A., & Huchon, C. (2016). External validation of the MR imaging scoring system for the management of adnexal masses. Eur J Obstet Gynecol Reprod Biol, 205, 115-119. doi:10.1016/j.ejogrb.2016.07.493

Rustin, G. J., Nelstrop, A. E., Tuxen, M. K., & Lambert, H. E. (1996). Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol, 7(4), 361-364. 

Rustin, G. J., Quinn, M., Thigpen, T., du Bois, A., Pujade-Lauraine, E., Jakobsen, A., . . . Vermorken, J. (2004). Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst, 96(6), 487-488. 

Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., . . . Swart, A. M. (2010). Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet, 376(9747), 1155-1163. doi:10.1016/s0140-6736(10)61268-8

Rustin, G. J., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., . . . Gynecological Cancer, I. (2011). Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer, 21(2), 419-423. doi:10.1097/IGC.0b013e3182070f17

Rutten, M. J., Leeflang, M. M., Kenter, G. G., Mol, B. W., & Buist, M. (2014). Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database Syst Rev, 2, CD009786. doi:10.1002/14651858.CD009786.pub2

Sabatucci, I., Maltese, G., Lepori, S., Tripodi, E., Bogani, G., & Lorusso, D. (2018). Rucaparib: a new treatment option for ovarian cancer. Expert Opin Pharmacother, 19(7), 765-771. doi:10.1080/14656566.2018.1464557

Sadowski, E. A., Robbins, J. B., Rockall, A. G., & Thomassin-Naggara, I. (2018). A systematic approach to adnexal masses discovered on ultrasound: the ADNEx MR scoring system. Abdom Radiol (NY), 43(3), 679-695. doi:10.1007/s00261-017-1272-7

Sadowski, E. A., Rockall, A. G., Maturen, K. E., Robbins, J. B., & Thomassin-Naggara, I. (2018). Adnexal lesions: Imaging strategies for ultrasound and MR imaging. Diagn Interv Imaging. doi:10.1016/j.diii.2018.06.003

Salehi, S., Mohammar, R., Suzuki, C., Joneborg, U., Hjerpe, E., Torbrand, C., & Falconer, H. (2018). Cardiophrenic lymph node resection in advanced ovarian cancer: surgical outcomes, pre- and postoperative imaging. Acta Oncol, 57(6), 820-824. doi:10.1080/0284186x.2017.1409434

Sarrel, P. M., Sullivan, S. D., & Nelson, L. M. (2016). Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertil Steril, 106(7), 1580-1587. doi:10.1016/j.fertnstert.2016.09.018

Sartori, E., Chiudinelli, F., Pasinetti, B., & Maggino, T. (2009). Bowel obstruction and survival in patients with advanced ovarian cancer: analysis of prognostic variables. Int J Gynecol Cancer, 19(1), 54-57. doi:10.1111/IGC.0b013e318198ff4b

Satoh, T., Hatae, M., Watanabe, Y., Yaegashi, N., Ishiko, O., Kodama, S., . . . Yoshikawa, H. (2010). Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol, 28(10), 1727-1732. doi:10.1200/JCO.2009.24.8617

SBU. Nedkylning av hårbotten för att förhindra håravfall i samband med cytostatikabehandling. Stockholm: Statens beredning för medicinsk utvärdering (SBU); 2005. SBU Alert-rapport nr 2005-06. ISSN 1652-7151 

SBU. Skattning av njurfunktion: en systematisk litteraturöversikt. Stockholm: Statens beredning för medicinsk utvärdering (SBU; 2013)

Schenberg, T., & Mitchell, G. (2014). Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review. Front Oncol, 4, 21. doi:10.3389/fonc.2014.00021

Schilder, J. M., Thompson, A. M., DePriest, P. D., Ueland, F. R., Cibull, M. L., Kryscio, R. J., . . . van Nagell, J. (2002). Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol, 87(1), 1-7. 

Schlaerth, A. C., Chi, D. S., Poynor, E. A., Barakat, R. R., & Brown, C. L. (2009). Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer, 19(7), 1199-1204. doi:10.1111/IGC.0b013e31819d82c3

Schmeler, K. M., Sun, C. C., Bodurka, D. C., White, K. G., Soliman, P. T., Uyei, A. R., . . . Lu, K. H. (2006). Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol, 108(3 Pt 1), 515-520. doi:10.1097/01.Aog.0000228959.30577.13

Schouten, L. J., Rivera, C., Hunter, D. J., Spiegelman, D., Adami, H. O., Arslan, A., . . . Smith-Warner, S. A. (2008). Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev, 17(4), 902-912. doi:10.1158/1055-9965.EPI-07-2524

Sehouli, J., Stengel, D., Oskay-Oezcelik, G., Zeimet, A. G., Sommer, H., Klare, P., . . . Lichtenegger, W. (2008). Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol, 26(19), 3176-3182. doi:10.1200/JCO.2007.15.1258

Seidman, J. D., & Kurman, R. J. (2000). Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol, 31(5), 539-557. 

Seidman, J. D., Kurman, R. J., & Ronnett, B. M. (2003). Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol, 27(7), 985-993. 

Seidman, J. D., Soslow, R. A., Vang, R., Berman, J. J., Stoler, M. H., Sherman, M. E., . . . Copeland, L. J. (2004). Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol, 35(8), 918-933. 

Sekse, R. J., Hufthammer, K. O., & Vika, M. E. (2014). Fatigue and quality of life in women treated for various types of gynaecological cancers: a cross-sectional study. J Clin Nurs. doi:10.1111/jocn.12647

Seruga, B., Zhang, H., Bernstein, L. J., & Tannock, I. F. (2008). Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer, 8(11), 887-899. doi:10.1038/nrc2507

Shah, C. A., Lowe, K. A., Paley, P., Wallace, E., Anderson, G. L., McIntosh, M. W., . . . Drescher, C. W. (2009). Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev, 18(5), 1365-1372. doi:10.1158/1055-9965.EPI-08-1034

Sharp, L., Johansson, H., Hatschek, T., & Bergenmar, M. (2013). Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast, 22(5), 634-638. doi:10.1016/j.breast.2013.07.047

Sherman, M. E., Mink, P. J., Curtis, R., Cote, T. R., Brooks, S., Hartge, P., & Devesa, S. (2004). Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer, 100(5), 1045-1052. doi:10.1002/cncr.20080

Shih Ie, M., & Kurman, R. J. (2004). Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol, 164(5), 1511-1518. 

Sieh, W., Salvador, S., McGuire, V., Weber, R. P., Terry, K. L., Rossing, M. A., . . . Ovarian Cancer Association, C. (2013). Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol, 42(2), 579-589. doi:10.1093/ije/dyt042

Singer, G., Stohr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D. F., . . . Shih Ie, M. (2005). Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol, 29(2), 218-224. 

Singh, N., Benson, J. L., Gan, C., Anglesio, M., Arora, R., Faruqi, A. Z., . . . McCluggage, W. G. (2018). Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage. Int J Gynecol Pathol, 37(4), 324-330. doi:10.1097/pgp.0000000000000429

Singh, N., Gilks, C. B., Hirshowitz, L., Wilkinson, N., & McCluggage, W. G. (2016). Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma: The Time has Come. Int J Gynecol Pathol, 35(3), 230-237. doi:10.1097/pgp.0000000000000270

Sioulas, V. D., Schiavone, M. B., Kadouri, D., Zivanovic, O., Roche, K. L., O'Cearbhaill, R., . . . Chi, D. S. (2017). Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? Gynecol Oncol, 145(1), 15-20. doi:10.1016/j.ygyno.2017.02.023

Skates, S. J., Greene, M. H., Buys, S. S., Mai, P. L., Brown, P., Piedmonte, M., . . . Lu, K. H. (2017). Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res, 23(14), 3628-3637. doi:10.1158/1078-0432.Ccr-15-2750

Skipper, H. E. (1978). Adjuvant chemotherapy. Cancer, 41(3), 936-940. 

Skirnisdottir, I., Garmo, H., Wilander, E., & Holmberg, L. (2008). Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer, 123(8), 1897-1901. doi:10.1002/ijc.23724

Smith, E. M., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., . . . Alliance for Clinical Trials in, O. (2013). Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA, 309(13), 1359-1367. doi:10.1001/jama.2013.2813

Smith, I., Kranke, P., Murat, I., Smith, A., O'Sullivan, G., Soreide, E., . . . in't Veld, B. (2011). Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol, 28(8), 556-569. doi:10.1097/EJA.0b013e3283495ba1

Song, H., Dicks, E., Ramus, S. J., Tyrer, J. P., Intermaggio, M. P., Hayward, J., . . . Pharoah, P. D. (2015). Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J Clin Oncol, 33(26), 2901-2907. doi:10.1200/jco.2015.61.2408

Song, T., Hun Choi, C., Lee, Y. Y., Kim, T. J., Lee, J. W., Bae, D. S., & Kim, B. G. (2011). Oncologic and reproductive outcomes of cystectomy compared with oophorectomy as a treatment for borderline ovarian tumours. Hum Reprod, 26(8), 2008-2014. doi:10.1093/humrep/der119

Song, T., Kim, M. K., Jung, Y. W., Yun, B. S., Seong, S. J., Choi, C. H., . . . Bae, D. S. (2018). The role of appendectomy in patients with mucinous borderline ovarian tumors. Eur J Obstet Gynecol Reprod Biol, 229, 112-116. doi:10.1016/j.ejogrb.2018.06.034

Soslow, R. A. (2008). Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol, 27(2), 161-174. doi:10.1097/PGP.0b013e31815ea812

Speck, R. M., Courneya, K. S., Masse, L. C., Duval, S., & Schmitz, K. H. (2010). An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv, 4(2), 87-100. doi:10.1007/s11764-009-0110-5

Stark, D., Nankivell, M., Pujade-Lauraine, E., Kristensen, G., Elit, L., Stockler, M., . . . Perren, T. (2013). Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol, 14(3), 236-243. doi:10.1016/S1470-2045(12)70567-3

Stashwick, C., Post, M. D., Arruda, J. S., Spillman, M. A., Behbakht, K., Davidson, S. A., & Kelly, M. G. (2011). Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer, 21(8), 1422-1427. doi:10.1097/IGC.0b013e31822c7704

Stead, M. L., Brown, J. M., Fallowfield, L., & Selby, P. (2003). Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. Br J Cancer, 88(5), 666-671. doi:10.1038/sj.bjc.6600799

Stewart, D. E., Wong, F., Duff, S., Melancon, C. H., & Cheung, A. M. (2001). "What doesn't kill you makes you stronger": an ovarian cancer survivor survey. Gynecol Oncol, 83(3), 537-542. doi:10.1006/gyno.2001.6437

Stockler, M. R., Hilpert, F., Friedlander, M., King, M. T., Wenzel, L., Lee, C. K., . . . Pujade-Lauraine, E. (2014). Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol, 32(13), 1309-1316. doi:10.1200/JCO.2013.51.4240

Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S., Ritterhouse, L. L., Liu, J. F., . . . Konstantinopoulos, P. A. (2016). Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget, 7(12), 13587-13598. doi:10.18632/oncotarget.7277

Stöd i arbetet med levnadsvanor. Retrieved from https://www.socialstyrelsen.se/nationellariktlinjerpreventionochbehandlingvidohalsosammalevnadsvanor/stodiarbetetmedlevnadsvanor

Sueblinvong, T., & Carney, M. E. (2009). Current understanding of risk factors for ovarian cancer. Curr Treat Options Oncol, 10(1-2), 67-81. doi:10.1007/s11864-009-0108-2

Suppiah, S., Chang, W. L., Hassan, H. A., Kaewput, C., Asri, A. A. A., Saad, F. F. A., . . . Vinjamuri, S. (2017). Systematic Review on the Accuracy of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography/Magnetic Resonance Imaging in the Management of Ovarian Cancer: Is Functional Information Really Needed? World J Nucl Med, 16(3), 176-185. doi:10.4103/wjnm.WJNM_31_17

Surampudi, K., Nirmalan, P. K., Gundabattula, S. R., & Chandran, J. B. (2015). Management of adnexal masses in pregnancy: our experience from a tertiary referral perinatal centre in South India. Arch Gynecol Obstet, 291(1), 53-58. doi:10.1007/s00404-014-3395-1

Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., . . . McNeish, I. A. (2017). Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol, 18(1), 75-87. doi:10.1016/s1470-2045(16)30559-9

Tada, H., Teramukai, S., Fukushima, M., & Sasaki, H. (2009). Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma. BMC Cancer, 9, 47. doi:10.1186/1471-2407-9-47

Tantitamit, T., & Lee, C. L. (2018). Is It the Time for Laparoscopic Management of Early-stage Ovarian Malignancies? Gynecol Minim Invasive Ther, 7(3), 93-103. doi:10.4103/gmit.Gmit_59_18

Tavtigian, S. V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., . . . Goldgar, D. E. (1996). The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet, 12(3), 333-337. doi:10.1038/ng0396-333

Tebes, S. J., Sayer, R. A., Palmer, J. M., Tebes, C. C., Martino, M. A., & Hoffman, M. S. (2007). Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol, 106(3), 482-487. doi:10.1016/j.ygyno.2007.04.006

Tholander B. Cancer och graviditet. I Obstetrisk öppenvård. Red. Marsal, Grennert Liber 2004; 161-172. 

Thomassin-Naggara, I., Aubert, E., Rockall, A., Jalaguier-Coudray, A., Rouzier, R., Darai, E., & Bazot, M. (2013). Adnexal masses: development and preliminary validation of an MR imaging scoring system. Radiology, 267(2), 432-443. doi:10.1148/radiol.13121161

Thomassin-Naggara, I., Darai, E., Cuenod, C. A., Fournier, L., Toussaint, I., Marsault, C., & Bazot, M. (2009). Contribution of diffusion-weighted MR imaging for predicting benignity of complex adnexal masses. Eur Radiol, 19(6), 1544-1552. doi:10.1007/s00330-009-1299-4

Thomsen, T., Villebro, N., & Moller, A. M. (2014). Interventions for preoperative smoking cessation. Cochrane Database Syst Rev(3), Cd002294. doi:10.1002/14651858.CD002294.pub4

Timmerman, D., Ameye, L., Fischerova, D., Epstein, E., Melis, G. B., Guerriero, S., . . . Valentin, L. (2010). Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ, 341, c6839. doi:10.1136/bmj.c6839

Timmerman, D., Testa, A. C., Bourne, T., Ameye, L., Jurkovic, D., Van Holsbeke, C., . . . Valentin, L. (2008). Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol, 31(6), 681-690. doi:10.1002/uog.5365

Timmerman, D., Testa, A. C., Bourne, T., Ferrazzi, E., Ameye, L., Konstantinovic, M. L., . . . International Ovarian Tumor Analysis, G. (2005). Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol, 23(34), 8794-8801. doi:10.1200/JCO.2005.01.7632

Timmerman, D., Van Calster, B., Testa, A., Savelli, L., Fischerova, D., Froyman, W., . . . Valentin, L. (2016). Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol, 214(4), 424-437. doi:10.1016/j.ajog.2016.01.007

Tinger, A., Waldron, T., Peluso, N., Katin, M. J., Dosoretz, D. E., Blitzer, P. H., . . . Orr, J. W., Jr. (2001). Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. Int J Radiat Oncol Biol Phys, 51(5), 1256-1263. 

Tingulstad, S., Hagen, B., Skjeldestad, F. E., Onsrud, M., Kiserud, T., Halvorsen, T., & Nustad, K. (1996). Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol, 103(8), 826-831. 

TLV. Avastin (bevacizumab) Hälsoekonomiskt kunskapsunderlag. December 2013. Diarienummer: 3676/2012. 

Tonnesen, H., Nielsen, P. R., Lauritzen, J. B., & Moller, A. M. (2009). Smoking and alcohol intervention before surgery: evidence for best practice. Br J Anaesth, 102(3), 297-306. doi:10.1093/bja/aen401

Travis, L. B., Holowaty, E. J., Bergfeldt, K., Lynch, C. F., Kohler, B. A., Wiklund, T., . . . Stovall, M. (1999). Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med, 340(5), 351-357. doi:10.1056/NEJM199902043400504

Trillsch, F., Mahner, S., Ruetzel, J., Harter, P., Ewald-Riegler, N., Jaenicke, F., & du Bois, A. (2010). Clinical management of borderline ovarian tumors. Expert Rev Anticancer Ther, 10(7), 1115-1124. doi:10.1586/era.10.90

Tseng, J. H., Cowan, R. A., Afonso, A. M., Zhou, Q., Iasonos, A., Ali, N., . . . Long Roche, K. (2018). Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer. Gynecol Oncol, 151(2), 287-293. doi:10.1016/j.ygyno.2018.08.024

Tunca, J. C., Buchler, D. A., Mack, E. A., Ruzicka, F. F., Crowley, J. J., & Carr, W. F. (1981). The management of ovarian-cancer-caused bowel obstruction. Gynecol Oncol, 12(2 Pt 1), 186-192. 

Tung, N., Domchek, S. M., Stadler, Z., Nathanson, K. L., Couch, F., Garber, J. E., . . . Robson, M. E. (2016). Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol, 13(9), 581-588. doi:10.1038/nrclinonc.2016.90

Tuxen, M. K., Soletormos, G., Rustin, G. J., Nelstrop, A. E., & Dombernowsky, P. (2000). Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer. Scand J Clin Lab Invest, 60(8), 713-721. 

Tworoger, S. S., Fairfield, K. M., Colditz, G. A., Rosner, B. A., & Hankinson, S. E. (2007). Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol, 166(8), 894-901. doi:10.1093/aje/kwm157

Wagner, B. E., Langstraat, C. L., McGree, M. E., Weaver, A. L., Sarangi, S., Mokri, B., . . . Bakkum-Gamez, J. N. (2019). Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer. Gynecol Oncol, 152(2), 286-292. doi:10.1016/j.ygyno.2018.11.021

Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., . . . Lauraine, E. P. (2012). Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer, 107(4), 588-591. doi:10.1038/bjc.2012.307

Valentin, L., Ameye, L., Savelli, L., Fruscio, R., Leone, F. P., Czekierdowski, A., . . . Timmerman, D. (2011). Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help. Ultrasound Obstet Gynecol, 38(4), 456-465. doi:10.1002/uog.9030

Valentin, L., Skoog, L., & Epstein, E. (2003). Frequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation. Ultrasound Obstet Gynecol, 22(3), 284-289. doi:10.1002/uog.212

Van Calster, B., Van Hoorde, K., Valentin, L., Testa, A. C., Fischerova, D., Van Holsbeke, C., . . . Timmerman, D. (2014). Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ, 349, g5920. doi:10.1136/bmj.g5920

Van Calsteren, K., Berteloot, P., Hanssens, M., Vergote, I., Amant, F., Ganame, J., . . . De Muylder, X. (2006). In utero exposure to chemotherapy: effect on cardiac and neurologic outcome. J Clin Oncol, 24(12), e16-17. doi:10.1200/JCO.2006.06.1382

van de Laar, R., Massuger, L. F., Van Gorp, T., IntHout, J., Zusterzeel, P. L., & Kruitwagen, R. F. (2015). External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer. Gynecol Oncol, 137(2), 210-215. doi:10.1016/j.ygyno.2015.02.004

Van der Hoeven, N. M. A., Van Wijk, K., Bonfrer, S. E., Beltman, J. J., Louwe, L. A., De Kroon, C. D., . . . Gaarenstroom, K. N. (2018). Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review. Clin Oncol (R Coll Radiol), 30(8), 463-471. doi:10.1016/j.clon.2018.03.036

van Driel, W. J., Koole, S. N., Sikorska, K., Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H. M., . . . Sonke, G. S. (2018). Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med, 378(3), 230-240. doi:10.1056/NEJMoa1708618

Van Gorp, T., Cadron, I., Despierre, E., Daemen, A., Leunen, K., Amant, F., . . . Vergote, I. (2011). HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer, 104(5), 863-870. doi:10.1038/sj.bjc.6606092

van Leeuwen, F. E., Klip, H., Mooij, T. M., van de Swaluw, A. M., Lambalk, C. B., Kortman, M., . . . Burger, C. W. (2011). Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod, 26(12), 3456-3465. doi:10.1093/humrep/der322

Vasconcelos, I., Darb-Esfahani, S., & Sehouli, J. (2016). Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates. BJOG, 123(4), 498-508. doi:10.1111/1471-0528.13840

Vasey, P. A., Jayson, G. C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., . . . Kaye, S. B. (2004). Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst, 96(22), 1682-1691. doi:10.1093/jnci/djh323

Watson, P., Butzow, R., Lynch, H. T., Mecklin, J. P., Jarvinen, H. J., Vasen, H. F., . . . Bernstein, I. (2001). The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol, 82(2), 223-228. doi:10.1006/gyno.2001.6279

Webb, J. A., Thomsen, H. S., Morcos, S. K., & Members of Contrast Media Safety Committee of European Society of Urogenital, R. (2005). The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol, 15(6), 1234-1240. doi:10.1007/s00330-004-2583-y

Weimann, A., Braga, M., Carli, F., Higashiguchi, T., Hubner, M., Klek, S., . . . Singer, P. (2017). ESPEN guideline: Clinical nutrition in surgery. Clin Nutr, 36(3), 623-650. doi:10.1016/j.clnu.2017.02.013

Wells, M., Macmillan, M., Raab, G., MacBride, S., Bell, N., MacKinnon, K., . . . Munro, A. (2004). Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol, 73(2), 153-162. doi:10.1016/j.radonc.2004.07.032

Wengstrom, Y., Bolam, K. A., Mijwel, S., Sundberg, C. J., Backman, M., Browall, M., . . . Rundqvist, H. (2017). Optitrain: a randomised controlled exercise trial for women with breast cancer undergoing chemotherapy. BMC Cancer, 17(1), 100. doi:10.1186/s12885-017-3079-x

Wenzel, L. B., Donnelly, J. P., Fowler, J. M., Habbal, R., Taylor, T. H., Aziz, N., & Cella, D. (2002). Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology, 11(2), 142-153. 

Wenzel, L. B., Huang, H. Q., Armstrong, D. K., Walker, J. L., Cella, D., & Gynecologic Oncology, G. (2007). Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol, 25(4), 437-443. doi:10.1200/JCO.2006.07.3494

Vergote, I., De Brabanter, J., Fyles, A., Bertelsen, K., Einhorn, N., Sevelda, P., . . . Trope, C. G. (2001). Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet, 357(9251), 176-182. doi:10.1016/S0140-6736(00)03590-X

Vergote, I., Trope, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., . . . Group, N. C. T. (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med, 363(10), 943-953. doi:10.1056/NEJMoa0908806

Werness, B. A., Ramus, S. J., Whittemore, A. S., Garlinghouse-Jones, K., Oakley-Girvan, I., Dicioccio, R. A., . . . Piver, M. S. (2000). Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol, 31(11), 1420-1424. 

Whittemore, A. S., Balise, R. R., Pharoah, P. D., Dicioccio, R. A., Oakley-Girvan, I., Ramus, S. J., . . . Piver, M. S. (2004). Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer, 91(11), 1911-1915. doi:10.1038/sj.bjc.6602239

Whittemore, A. S., Harris, R., & Itnyre, J. (1992). Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol, 136(10), 1184-1203. 

Wilbur, M. A., Shih, I. M., Segars, J. H., & Fader, A. N. (2017). Cancer Implications for Patients with Endometriosis. Semin Reprod Med, 35(1), 110-116. doi:10.1055/s-0036-1597120

Williams, C., Simera, I., & Bryant, A. (2010). Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev(3), CD001034. doi:10.1002/14651858.CD001034.pub2

Wimberger, P., Wehling, M., Lehmann, N., Kimmig, R., Schmalfeldt, B., Burges, A., . . . du Bois, A. (2010). Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol, 17(6), 1642-1648. doi:10.1245/s10434-010-0964-9

Visioni, A., Shah, R., Gabriel, E., Attwood, K., Kukar, M., & Nurkin, S. (2018). Enhanced Recovery After Surgery for Noncolorectal Surgery?: A Systematic Review and Meta-analysis of Major Abdominal Surgery. Ann Surg, 267(1), 57-65. doi:10.1097/sla.0000000000002267

von Moos, R., Thuerlimann, B. J., Aapro, M., Rayson, D., Harrold, K., Sehouli, J., . . . Hauschild, A. (2008). Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer, 44(6), 781-790. doi:10.1016/j.ejca.2008.01.028

Wong, M., O'Neill, S., Walsh, G., & Smith, I. E. (2013). Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann Oncol, 24(1), 133-138. doi:10.1093/annonc/mds250

Woopen, H., & Sehouli, J. (2009). Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res, 29(8), 3353-3359. 

World Health, O., International Agency for Research on, C., & Kurman, R. J. (2014). WHO Classification of Tumours of Female Reproductive Organs [Elektronisk resurs]: International Agency for Research on Cancer.

Wright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., . . . Edelson, M. I. (2016). Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol, 143(1), 3-15. doi:10.1016/j.ygyno.2016.05.022

Wright, J. D., Herzog, T. J., Siddiq, Z., Arend, R., Neugut, A. I., Burke, W. M., . . . Hershman, D. L. (2012). Failure to rescue as a source of variation in hospital mortality for ovarian cancer. J Clin Oncol, 30(32), 3976-3982. doi:10.1200/JCO.2012.43.2906

Xiao, Q., Yang, H. P., Wentzensen, N., Hollenbeck, A., & Matthews, C. E. (2013). Physical activity in different periods of life, sedentary behavior, and the risk of ovarian cancer in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev, 22(11), 2000-2008. doi:10.1158/1055-9965.EPI-13-0154

Yarandi, F., Eftekhar, Z., Izadi-Mood, N., & Shojaei, H. (2008). Accuracy of intraoperative frozen section in the diagnosis of ovarian tumors. Aust N Z J Obstet Gynaecol, 48(4), 438-441. doi:10.1111/j.1479-828X.2008.00873.x

Yen, C. F., Lin, S. L., Murk, W., Wang, C. J., Lee, C. L., Soong, Y. K., & Arici, A. (2009). Risk analysis of torsion and malignancy for adnexal masses during pregnancy. Fertil Steril, 91(5), 1895-1902. doi:10.1016/j.fertnstert.2008.02.014

Yoo, H. J., Lim, M. C., Song, Y. J., Jung, Y. S., Kim, S. H., Yoo, C. W., & Park, S. Y. (2013). Transabdominal cardiophrenic lymph node dissection (CPLND) via incised diaphragm replace conventional video-assisted thoracic surgery for cytoreductive surgery in advanced ovarian cancer. Gynecol Oncol, 129(2), 341-345. doi:10.1016/j.ygyno.2012.12.023

Young, R. C., Walton, L. A., Ellenberg, S. S., Homesley, H. D., Wilbanks, G. D., Decker, D. G., . . . Major, F., Jr. (1990). Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med, 322(15), 1021-1027. doi:10.1056/NEJM199004123221501

Yuan, Y., Gu, Z. X., Tao, X. F., & Liu, S. Y. (2012). Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis. Eur J Radiol, 81(5), 1002-1006. doi:10.1016/j.ejrad.2011.01.112

Zanetta, G., Rota, S., Chiari, S., Bonazzi, C., Bratina, G., & Mangioni, C. (2001). Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol, 19(10), 2658-2664. 

Zapardiel, I., Peiretti, M., Zanagnolo, V., Biffi, R., Bocciolone, L., Landoni, F., . . . Maggioni, A. (2011). Diaphragmatic surgery during primary cytoreduction for advanced ovarian cancer: peritoneal stripping versus diaphragmatic resection. Int J Gynecol Cancer, 21(9), 1698-1703. doi:10.1097/IGC.0b013e31822f65c3

Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., . . . Coukos, G. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med, 348(3), 203-213. doi:10.1056/NEJMoa020177

Zhou, B., Sun, Q., Cong, R., Gu, H., Tang, N., Yang, L., & Wang, B. (2008). Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol, 108(3), 641-651. doi:10.1016/j.ygyno.2007.12.003

Zikan, M., Fischerova, D., Pinkavova, I., Dundr, P., & Cibula, D. (2010). Ultrasound-guided tru-cut biopsy of abdominal and pelvic tumors in gynecology. Ultrasound Obstet Gynecol, 36(6), 767-772. doi:10.1002/uog.8803

Zivanovic, O., Sonoda, Y., Diaz, J. P., Levine, D. A., Brown, C. L., Chi, D. S., . . . Abu-Rustum, N. R. (2008). The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol, 111(3), 431-437. doi:10.1016/j.ygyno.2008.08.024


Nästa kapitel
23 Länkar, definitioner, förkortningar